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My name is Ann Lykkegaard Sørensen, and this CV presents my professional 
background and the journey which led to the completion of my PhD study. I
became a registered nurse from The Aalborg School of Nursing in 2000 and went 
on to work with medical, surgical, and psychiatric patients. In 2006, I enrolled at 
Aarhus University and obtained a Master’s degree in Health Science (MHSc) in 
2010. Upon completing my Master’s degree, I became a lecturer at University 
College of North Jutland, and I am still there today.
My Master’s thesis and other projects were concerned with patient - and medication 
safety, which specifically spurred my interest in medication safety and my 
awareness of potentially inappropriate prescribing in psychiatric nursing. I enrolled 
as a PhD student February 1, 2012, at the Department of Health Sciences and 
Technology, Aalborg University.
My research has been aimed at medication safety in the field of psychiatry. I used 
systematic medication reviews performed by clinical pharmacologists, to 
investigate the characteristics of potentially inappropriate prescribing, and 
investigate the role of psychiatric nurses in improving medication safety by 




Medication errors are the most frequent adverse incidents in healthcare systems 
across the world causing increased mortality, morbidity, and increased costs for 
both society and patients. Potentially inappropriate prescriptions (PIPs) also lead to 
increased mortality, morbidity, and increased health care costs. However, PIPs are 
primarily studied in the elderly. The exclusion of psychiatric patients is common to 
these studies of medication errors and PIPs. Hence, the aim of this PhD thesis was 
to investigate the prevalence and potentially clinical consequences of medication 
errors and PIPs, as well as nurses’ ability to identify PIPs for psychiatric patients 
validated by comparing with the findings of senior clinical pharmacology 
physicians’ (SCPP) medication reviews. Finally, the aim was also to discover 
nurses’ perceptions of nurse-physician collaboration (NPC) on medication 
optimisation.
The four studies were comprised of two cross-sectional studies, one controlled 
before-and-after study including psychiactric patients admitted to bed units in the 
North Denmark Region, and one qualitative thematic study. In Study I, three 
methods were applied to collect data (observation, unannounced visits, and chart 
audit), for the purpose of identifying errors in the medication process. The results of
Study I showed errors in 17% of all opportunities for error and 8% of errors in the 
medication were assessed to be potentially harmful and were thus being medication 
errors. In the next cross-sectional study, Study II, systematic medication reviews 
were applied by SCPPs to identify PIPs and to assess potential clinical 
consequences. The study included all psychiatric patients admitted to a bed unit in 
the North Denmark Region over a three-month period. The results in Study II 
demonstrated 349 PIPs in 1291 prescriptions with 33% of patients affected by at 
least one potentially serious prescription and 12% of patients affected by at least 
one potentially fatal prescription. Study III, was a controlled before-and-after study, 
with a two-month baseline and a six-month follow-up period, where all patients 
received a medication review by SCPPs and these medication reviews were 
considered gold standard. The intervention consisted of a pharmacology training 
course for nurses in the intervention bed units and afterwards the nurses reviewed 
medication lists to identify PIPs. The study was carried out in two intervention bed 
units and two control bed units. Primary outcomes were the SCPPs identification of 
PIPs, before and during the intervention, but adjusted for the nurses’ identifications 
of PIPs during the intervention. Results indicated potential improvement in the 
mean number of PIPs per patient and the number of patients with at least one PIP. 
Secondary outcomes counted the prevalence and types of PIPs altered by physicians 
as a consequence of nurses observations. Study IV, the final study, was a qualitative 
thematic analysis of the nurses’ perceptions of NPC on medication optimisation for 
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psychiatric patients. The nurses described challenges with NPC relating to both 
individual as well as organisational factors. 
Conclusively, this PhD thesis demonstrates that errors, medication errors and PIPs 
are frequent in psychiatric patients. Nurses reviewing patients’ medications could 
only produce non-significant potential improvements. These results should be 
viewed in the light of the fact that the nurses described a perceived everyday work 
environment, in which beneficial NPC regarding medication optimisation was not 
given due consideration. Future studies should, on a larger scale, focus on how and 
by which methods nurses may contribute to better observation, identification, and 
reporting of errors and the inappropriate use of medication in psychiatry.
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DANSK RESUME
Globalt set er medicineringsfejl på hospitaler den hyppigste utilsigtede hændelse og
årsag til øget mortalitet, morbiditet og ekstra omkostninger for både samfund og
patienter. Potentielt uhensigtsmæssige ordinationer (potentially inappropriate 
prescriptions (engelsk:PIP)) har også vist sig at medføre øget mortalitet, morbiditet
og ekstra omkostninger, men er primært undersøgt for ældre patienter. Fælles for 
studier af medicineringsfejl og PIPs er, at psykiatriske patienter kun sjældent har 
været inkluderet. Formålet med denne afhandling var at undersøge prævalens og
potentielle, kliniske konsekvenser af medicineringsfejl og PIPs, samt
sygeplejerskers evne til at identificere PIPs hos psykiatriske patienter valideret ved 
sammenligning med kliniske farmakologers medicingennemgang. Endelig var det 
også formålet at afdække sygeplejerskers oplevelser af samarbejdet med læger om 
at sikre den bedst mulige medicinske behandling af patienter. 
Studierne består af to tværsnitsstudier, et kontrolleret før-og-efter studie samt et 
kvalitativt tematisk studie. I studie I blev data indsamlet på tre sengeafsnit ved 
hjælp af tre metoder (observation, kontrolbesøg samt journalaudit), med henblik på 
identifikation af fejl i medicineringsprocessen. Disse fejl blev vurderet af kliniske 
farmakologer for potentiel klinisk alvorlighed. Resultaterne viste at der var fejl i 
17% af alle muligheder for fejl og at 8% af fejlene i medicineringsprocessen blev 
vurderet som potentielt skadelige og dermed medicineringsfejl. Efterfølgende blev 
der udført yderligere et tværsnitsstudie, studie II, hvor kliniske farmakologer ved 
hjælp af systematisk medicingennemgang identificerede potentielt 
uhensigtsmæssige ordinationer samt vurderede disse for potentiel klinisk 
alvorlighed. Studiet fandt sted over en tre måneders periode og inkluderede alle 
patienter indlagt på et psykiatrisk sengeafsnit i Region Nordjylland. Resultaterne i 
studie II viste 349 PIPs i 1291 ordinationer samt at 33% af patienterne havde mindst 
1 potentielt alvorlig uhensigtsmæssig ordination og 12% af patienterne havde 
mindst en potentielt fatal uhensigtsmæssig ordination. Studie III, et kontrolleret før-
og-efter studie, blev udført på fire psykiatriske sengeafsnit (to interventions afsnit
og to kontrol afsnit) over en otte måneders periode. De kliniske farmakologer 
udførte medicingennemgang for alle inkluderede patienter i studiet og betragtedes 
som gold standard. Interventionen bestod af et farmakologikursus for 
sygeplejerskerne på interventionssengeafsnittene. I interventionsperioden 
gennemgik sygeplejerskerne patienternes medicinlister efter indlæggelse med 
henblik på at identificere PIPs. Primære effektmål var de kliniske farmakologers 
identifikation af PIPs, før og under interventionen, men justeret for 
sygeplejerskernes identifikationer af PIPs under interventionen. Resultaterne 
indikerede potential forbedring i det gennemsnitlige antal PIPs per patient samt 
proportionen af patienter med mindst 1 PIP. Sekundære effektmål var prævalens og 
type af PIPs hvor læger ændrede ordinationer som konsekvens af sygeplejerskernes 
observationer. Sidste studie, studie IV, var en kvalitativ, tematisk analyse af 
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sygeplejerskernes opfattelse af samarbejdet med læger om at sikre den bedst mulige 
medicinske behandling af psykiatriske patienter. Sygeplejerskerne beskrev en 
række udfordringer i sygeplejerske-læge samarbejdet som relaterede sig både til 
individuelle såvel som organisatoriske forhold.
Samlet viser denne ph.d., at fejl, medicineringsfejl og potentielt uhensigtsmæssige 
ordinationer er hyppigt forekommende hos psykiatriske patienter. Det var kun 
muligt at vise ikke-signifikante potentielle forbedringer ved hjælp af 
sygeplejerskers gennemgang af medicin. Dette resultat skal ses i lyset af, at 
interventionen blev gennemført af sygeplejersker, der gav udtryk for en hverdag, 
hvor hensynet til et godt sygeplejerske-læge samarbejde omkring medicin 
optimering var begrænset. Fremtidige studier bør i større målestok fokusere på, 
hvordan og med hvilke metoder sygeplejersker kan bidrage til bedre observation, 
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‘Let whoever is in charge keep this simple question in her 
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1.1. RESEARCH IN MEDICATION SAFETY
Medical errors pose a major threat to patient safety worldwide, and medication 
errors (MEs) form the largest category of medical errors causing increased 
mortality, morbidity and costs to society as confirmed by meta-analyses, systematic 
reviews and individual studies (1–6). Iatrogenic injury had been demonstrated as a 
massive problem in the early 1990s and called for both public and professional 
attention (7–10). However, before the millennium change, these large studies of 
patient injury had little impact on the political agenda until in 2000, patient safety 
issues were raised with the launch of the Institute of Medicine report “To err is 
human” (11,12). This report claimed that as many as 98,000 patients die annually as
a result of medical errors (11). Worldwide, this statement sparked tremendous
activity in patient safety research and projects (13,14).
Psychiatric patients were systematically excluded in the high-impact studies in 
general medical settings on which the IOM based their recommendations, and thus 
little evidence on the incidence, types, and causes of error in psychiatric treatment 
is available (15). Most studies within the field of medication safety have focused 
exclusively on somatic hospital settings; consequently, there is little research on 
medication errors and adverse drug events in psychiatry (12,16). However, research 
has demonstrated that psychiatric in-patients do experience potential and actual 
harm from adverse drug events (ADEs) (17).
Additionally, there is only a limited body of research on potentially inappropriate 
prescriptions (PIPs) in psychiatry. Most of the existing research examines specific 
prescribing practices (18,19) or the inappropriate use of psychoactive drugs in other 
settings other than mental health (20,21). Attempts to improve the quality of 
prescribing have been assessed, singling out as the most successful methods audit-
feedback interventions and educational out-reach visits involving physicians and 
pharmacists (22). Despite the medication process being a multidisciplinary activity, 
very few attempts have been made to involve nurses’ observations in improving the 
quality of prescribing (23,24) and even less so in mental health settings. 
Consequently, it is reasonable to question the safety of the medication process and 
appropriateness of prescribing in mental health settings as well as to explore 
interventions and contexts which place nurses centrally in identifying and reporting 
PIPs.
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1.2. THE CONTEXT OF POTENTIALLY INAPPROPRIATE
PRESCRIPTIONS AND ERRORS IN THE MEDICATION 
PROCESS
To describe PIPs and errors in the medication process, I relied on work by Dean, 
Barber, and Schachter, Aronson and Ferner, and Lisby et al. (25–31). This section 
describes major points in the works of the authors mentioned above, relating to 
definitions and classifications of MEs in the context of PIPs.
1.2.1. PRESCRIPTION ERRORS AND CLINICAL DECISION-MAKING
Dean et al. distinguished between ‘errors in decision-making’ and ‘errors in 
prescription writing’ in their practitioner-led definition of a prescribing error 
achieved through a Delphi process (25). In defining prescribing errors, some 
respondents objected to including ‘errors in decision-making’, because a 
prescription error could be considered part of ‘clinical decision-making’ rather than 
‘prescribing’. However, both types of error remained in the final definition: 
‘A clinically meaningful prescribing error occurs when, as a result of a prescribing 
decision or prescription writing process, there is an unintentional significant 1) 
reduction in the probability of treatment being timely and effective or 2) increase in 
the risk of harm when compared with generally accepted practice.’ (25)
Thus, when applying the above definition, it is important to acknowledge the 
bisection. Dean et al. do not bring the term ‘inappropriate prescriptions’ into play
but, by linking prescription errors to clinical decision-making imply that the writing 
of a prescription is influenced by the available evidence, the individual physician’s 
knowledge and experience as well as patient preferences which provide 
opportunities for more or less appropriate decisions. 
1.2.2. PRESCRIPTION ERRORS, PRESCRIBING FAULTS, AND 
BALANCED PRESCRIBING
Robin E. Ferner co-authored a study with Sarah E. McDowell and Harriet S. Ferner 
in which the forms of error were discussed and, inspired by Kirwan (32), errors 
were described as a disorder of an intentional act which can be divided in two: 
formulating the plan for action, and executing of the plan (33). This duality of error 
is essential in understanding errors in the medication process. Aronson and Ferner
originally suggested the following definition of MEs:
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‘…a failure in the drug treatment process that leads to or has the potential to lead 
to, harm to the patient.’ (29)
Later the definition of an ME was adopted by European Medicines Agency (EMA)
with the addition of ‘unintended’: 
‘…an unintended failure in the treatment process that leads to or has the potential 
to lead to, harm to the patient’ (34)
Aronson distinguishes between ‘prescribing faults’ and ‘prescription errors’ (27)
arising from the ambiguity in the meanings ‘prescribing’ and ‘prescription’.
Comparing to the definition by Dean et al., ‘prescribing fault’ then means a 
‘[wrong] prescribing decision’ and ‘prescription error’ means an ‘[erroneous] 
prescription writing process’. Aronson mentions several types of prescribing faults: 
irrational prescribing, inappropriate prescribing, underprescribing, overprescribing, 
and ineffective prescribing and refers to this as ‘a class of errors’ (28). He suggests, 
however, that due to the substantial overlap between these types of faults, it is 
helpful to describe them by a definition of their opposite; balanced prescribing. 
Balanced prescribing is defined as:
‘…a process that recommends a medicine appropriate to the patient’s condition 
and, within the limits created by the uncertainty that attends therapeutic decisions,
a dosage regimen that optimizes the balance of benefit to harm.’ (28)
In the scope of Anderson’s work, inappropriate prescribing is a subclass of 
prescribing faults. 
1.2.3. DEFINING MEDICATION ERRORS
Lisby et al. developed and tested a definition of medication errors after reviewing 
45 studies presenting with a definition of a medication error (30,31), as follows:
‘…an error in the stages of the medication process – ordering, dispensing, 
administering, and monitoring the effect – causing harm or implying a risk of 
harming the patient.’
This definition had evolved through a Delphi process involving 13 Danish health 
organisations and thus represented the most acceptable definition to the participants 
(31). The definitions by Aronson and Ferner, and Lisby have obvious similarities as 
both point to harm, or the probability of harm, to the patient. However, the 
definition by Lisby et al. applies the term ‘an error in the stages of the medication 
process’ which is circular reasoning according to Aronson's thoughts on definitions 
and classification (26). Aronson uses this example: 
3
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‘…nor do as Dr. Johnson did in his 1755 dictionary and unhelpfully define a hind
as ‘she to a stag’ and a stag as ‘the male of the hind’.’ (26)
During their Delphi process, Lisby et al. received much protest against the word 
‘failure’, which appears to be used by Aronson and Ferner merely to avoid 
circularity and signifies ‘fallen below some attainable standard’ (29). This was not 
the association expressed by the Danish clinical experts who rejected the term 
‘failure’ as being imprecise and value-laden (31). It is likely, that in a Danish 
context, using the word ‘failure’ will be perceived as the individual ‘being a failure’ 
which is more shameful than ‘having made an error’. In the Delphi process led by 
Lisby et al., the clinical experts also approved a comprehensive list of error types, 
including prescription errors divided into the decision-making stage and 
communicating (writing) stage (31). The understanding of errors in the prescribing 
stage as being errors in clinical decision-making, or in the writing of a prescription, 
is also found with Lisby et al. According to Dean et al., an error in decision-making 
implies that the writing of a prescription is influenced by the available evidence, the 
individual physicians’ knowledge and experience as well as patient preferences 
which provide opportunities for more or less appropriate decisions.
1.2.4. OPERATIONAL DEFINITIONS
This subsection describes how ‘errors’, ‘MEs’, and ‘PIPs’ are defined in this thesis 
and its ancillary articles. In this thesis, error is to be understood as ‘a planned action 
which failed to achieve the desired consequences’ (35). However, when 
investigating prescription errors, it is beneficial to consider an error as an 
intentional act which can be considered in terms of the formulating of a plan or the 
actual execution of the plan (33). Medication errors are defined as errors in the 
stages of the medication process – ordering, dispensing, administering, and 
monitoring the effect – causing harm or implying a risk of harming the patient (31).
Likewise, using the definition by Lisby et al., errors are categorised in types, which 
are described in Appendix A. Intentionality by the physician would be the crux of 
the matter between error and rule violation and seen in conjunction with the 
prescribing of medications, means that it appears relatively straightforward whether 
or not an error is present in the communicating of a prescription. It appears less 
straightforward as to whether an error is present in the decision-making stage as
several factors influence the decisions made. The physician will rely on evidence, 
clinical experience, and viewpoints which may vary, together with the patient’s 
preferences and individual circumstances. An example to illustrate this concerns 
off-label prescribing in psychiatry. Off-label prescribing may take different forms, 
but one approach is to prescribe a dose higher than that recommended by, for 
example, the European Public Assessment Report. This is an intended (and possibly 
good) decision to make a rule violation, but not necessarily an error (although it 
might be). Whatever the case, error, or rule violation, the prescriber has increased 
the probability of the prescription being inappropriate. In this thesis, the term PIP is 
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defined as prescribing that introduces a significant risk of an adverse drug-related 
event where there is evidence for an equally or more effective but lower-risk 
alternative therapy available for the same condition. Additionally, PIP includes the 
use of drug combinations with known drug–drug interactions, drug–disease 
interactions, overdosing, use of drugs for a longer time than clinically indicated, as 
well as the omission of prescribing drugs that are clinically indicated (36,37).
Given the uncertainty surrounding prescribing in psychiatry, the term PIP allows for 
medications involving risk but possibly also benefit. In this thesis and its ancillary 
articles, a PIP, regardless of whether it involves an error or a rule violation (‘good’ 
or ‘bad’), is categorised in types adapted from the work of Lisby et al. 
1.3. THE EPISTEMOLOGY OF MEDICATION ERRORS
Researchers have suggested that <1% of all errors in the medication process 
actually cause harm to the patient (38). This indicates a need to discriminate 
between important and not-important errors in the medication process; in other 
words what can harm or not harm patients. The rationale for the given definition of 
an ME in this thesis was the distinction between harmful and harmless to the 
patient. It has been suggested that interventions focused on MEs with the potential 
for harming the patient might also bear the highest positive clinical impact (31,39–
41). This raises questions about the definition of MEs and, additionally, what 
constitutes an error in the medication process. The definitions used in studies of 
medication safety and iatrogenic harm are diverse, and even though attempts have 
been made to clarify terminology as well as methodology, there is still variation in 
the definitions presented in the literature (26,30,42). Several scholars have argued 
that this lack of consistency may cause difficulties in producing reliable estimates 
of patient safety; for instance MEs and ADEs (30,43–45).
The methodology used in the large epidemiological studies of ADEs and MEs 
(9,46,47) could, in all likelihood, be transferred to psychiatric settings, although 
certain aspects of psychiatric care have to be considered. The main goal in research 
on ADEs and MEs is to reduce the risk of patients experiencing harm due to 
medication use and to do so there is a need to establish epidemiological measures 
regarding the frequency, classification of events and any associations with other 
variables offering preventability (48,49). These epidemiological measures can be 
categorised under three headings: identification, classification, and risk factors, 
which will be clarified in the following sections. These sections also touch on 
complicating factors related to the psychiatric context.
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1.3.1. IDENTIFYING MEDICATION ERRORS
Identification of MEs is essential to improve medication safety, but the methods to 
do so all have their advantages and problems (49,50). Key approaches to the 
detection of MEs are voluntary reporting, retrospective chart reviews, computerised
monitoring, and searching claims data (48–52). Direct observation of patient care 
has, however, been identified as a superior yet costly method (51).
Voluntary incident reporting has been a pivotal part of safety initiatives in other 
fields with the aviation industry leading the way (53,54), and has been adopted by 
most healthcare institutions as the preferred method for detecting MEs and ADEs
(49). However, this method is less sensitive in detecting ADEs and MEs than any 
other method (51).
Retrospective chart review has proven to be well-suited for identifying ADEs, 
although not as effectively as direct observation of patient care. This method is also 
costly and time-consuming and requires that medical personnel correctly register 
any events that have taken place (51). Also, the reviewers’ assessments may display 
significant variance in identifying, for instance, ADEs (51).
Computerised monitoring is a programme consisting of rules which are applied to,
for instance, electronic medical records (EMRs) and indicate the possibility of an 
ADE being present (55). Studies have successfully demonstrated computerised
monitoring as a method of detecting ADEs (56,57). However, positive predictive 
values still need improvement as computerised monitors frequently alert to false 
positive ADEs (55).
Medication errors are, in this thesis and its ancillary articles, defined as: an error in 
the stages of the medicati , and 
(31).
1.3.2. RISK FACTORS FOR MEDICATION ERRORS
Studies have identified several risk factors for MEs (8,58–62). Risk factors can,
regardless of setting, be divided into three groups: 1) Patient-related factors 2) 
Health provider-related factors and 3) System-related factors (16).
Patient-related factors: In the psychiatric setting, patients often struggle with 
adherence to their medications. Though this is not always a medication error, it is 
strongly correlated to worsening of symptoms and rehospitalisation (63).The 
prevalence of substance abuse is higher in psychiatric patients than in the general 
population, and little is recognised about the clinical consequences of interactions 
between substance abuse and prescribed medications (64,65). Several psychiatric 
conditions often reduce the patients’ cognitive skills resulting in insufficient 
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communication about drug effects and side effects (16). Prescribing medication is 
complicated in psychiatry; the patients may lack trust in hospital staff (66,67), their 
conditions may be unstable and rapidly change (16), and the number of 
comorbidities is often high (60). These are all factors which obfuscate
understanding medication errors in psychiatry.
Provider-related factors: Decision-making errors are clinical errors, and two of 
the most frequent factors leading to these errors are insufficient knowledge of the 
patients clinical status and insufficient knowledge of the medications prescribed 
(47,61,68). Researchers have suggested that particularly junior physicians are 
associated with decision-making errors (47,68).
The use of psychotropic pro re nata (PRN) medications is frequent in psychiatric
wards and is a contributory factor to exposing patients to high doses of 
antipsychotics (69,70). A study showed that PRN administrations took place in the 
acute phase of 82% of all admissions. Additionally, medication-related morbidity 
was registered for more than a third of all patients receiving PRN drugs (70). The 
indications and reasons given for prescribing and administering, respectively, does 
not necessarily complement each other as physicians and nurses have different 
knowledge and beliefs about PRN medication; for example, 93% of nurses versus 
45% of physicians believe hallucinations/delusions is an appropriate indication for 
PRN treatment with an antipsychotic (71).
Off-label prescribing refers to situations where a medicinal product is intentionally 
used for a medical purpose, but not in accordance with the authorised product 
information (72). There is evidence that off-label prescribing in psychiatry is 
common (73,74). Off-label prescribing is often not supported by evidence (74) and 
should, therefore, initiate a higher level of attention towards medication safety.
Dispensing medications is also an opportunity for error. However, this has not been 
studied extensively although a Danish study, relying partially on direct observation 
rather than chart review, reported that the rate of dispensing error was 1.85/100 
opportunities for error (75).
Nurses are responsible for dispensing and administering medications, although 
several hospitals in Denmark also allow nurses’ assistants to dispense and 
administer medications. Nurses’ assistants have been included in the Medicines Act 
since 2014 and have an independent responsibility when handling medications (76).
Nurses have stated some of the following reasons for administration errors: busy 
work environment, unclear instructions, communication failure, confusion over 
sound-a-like medications, problematic drug administration area or storage, as well 
as personal factors (77).
7
MEDICATION SAFETY IN PSYCHIATRY
Adequate monitoring of patients is also essential in patient- and medication safety. 
Both physicians and nurses may fail to provide proper monitoring. For example; in 
a meta-analysis, the baseline screening for metabolic syndrome was found to be 
low. Only the measuring of blood pressure was above 50%. In fact, less than 25% 
of patients had their lipids, and glycosylated haemoglobin (HbA1c) measured (78).
In another study, nurses produced insufficient documentation on the effect of PRN 
medication, making it extremely difficult to evaluate any outcome (79).
System-related factors: Medication discrepancies are frequent various stages in 
hospital admissions and transitions of care and may lead to adverse events (80,81).
A system-related risk factor also involves a lack of pharmaceutical and 
pharmacological advice in mental health settings (16). However, although studies
are focusing on clinical pharmacists interventions so far have shown a reduction in 
medication errors (81,82) but on the other hand; similar pharmacist-led 
interventions have not produced solid evidence for improved patient outcomes
(83,84).
1.4. POTENTIALLY INAPPROPRIATE PRESCRIBING IN 
PSYCHIATRY
PIP is a term mainly used in the research literature on geriatric populations but is 
relevant for any patient population. Several researchers have examined PIPs in the 
elderly and have used similar but still slightly different definitions (85–88). The 
term ‘potentially’ signifies an understanding of prescribing as a somewhat 
subjective process influenced by evidence, personal experience, and attitudes as 
well as patients’ preferences (37,89). ‘Inappropriate’ (or appropriate) refers to the 
quality of prescribing and provides for more perspectives on prescribing than 
merely reducing it to a question of good/bad prescribing (90). PIP is a commonly 
used notion in medication safety, yet difficult to define precisely. However, in this 
thesis, PIP is defined as:
‘…prescribing that introduces a significant risk of an adverse drug-related event 
where there is evidence for an equally or more effective but lower-risk alternative 
therapy available for the same condition. Additionally, PIP includes the use of drug 
combinations with known drug–drug interactions, drug–disease interactions, 
overdosing, use of drugs for a longer time than clinically indicated, as well as the 
omission of prescribing drugs that are clinically indicated.’ (36,37)
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1.4.1. IDENTIFYING A POTENTIALLY INAPPROPRIATE PRESCRIPTION
Medication review is often used to detect PIP (91). Currently, there is no ‘golden 
standard’ on how, or by whom, medication reviews should be conducted (92,93).
However, a recent review a definition: a systematic assessment of the 
pharmacotherapy of an individual patient that aims to evaluate and optimise patient 
medication (or not) in prescription, either by a recommendation or by a direct 
change (92). This is only partly consistent with the understanding of medication
reviews in this thesis as recommendations and changes were not part of the study
design. Identifying PIPs has much in common with identifying medication errors. 
However, the research has tended to focus on the use of screening tools to identify 
PIPs and only in elderly populations. A recent review of published tools to identify 
PIPs in the elderly found a total of 46 tools which were divided into explicit, 
implicit and mixed approaches (94). Examples of screening tools frequently used in 
research are the Beers criteria (95), STOPP and START (96). There are no similar 
tools or criteria published for the identification of PIPs in psychiatric populations.
Explicit approaches are often designed as ‘checklists’ to detect PIPs (97–101).
Some of the advantages of explicit medication reviews are that they are cheap, 
simple, easy to apply and objective (89,90); disadvantages include not considering 
patients’ clinical situation and not addressing all aspects of prescribing, e.g. 
duration of therapy (89).
Implicit approaches include assessment tools such as the MAI-criteria which 
consist of ten questions used to assess the medication appropriateness of the 
medication (102) as well as the general medication review. Implicit medication 
reviews include all the medications prescribed to the patient, the patient’s history, 
the patient’s preferences, the best available evidence, and the experience and 
knowledge of the individual clinician (90,103). However, the method is more 
susceptible to subjectivity in assessment and, thereby, interrater variation 
(89,90,104)
Mixed approaches combine the advantages related to implicit and explicit 
approaches, and also the disadvantages.
In this thesis and its ancillary articles, PIPs are, classified into categories adapted 
from the error types in the decision-making stage of prescribing given in Appendix 
A. The resulting categories are shown in Appendix B.
1.4.2. RISK FACTORS FOR PIPS
There is a major overlap between the risk factors for MEs and PIPs. Descriptions of 
the patient-, provider-, and system related risk factors for MEs are found in Section 
1.3.2. Risk factors for PIPs in psychiatry in general have not been investigated,
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although, at least three recent studies have examined PIPs in elderly psychiatric 
patients, looking into the prevalence and risk factors of PIPs (105–107). The 
prevalence of PIPs, depending on the screening tool, was 53%-79% (106,107). All 
studies identified psychotropic drugs and polypharmacy as being associated with 
PIPs. Other risk factors identified were cognitive impairment, previous falls and 
hospitalisations, somatic comorbidity and living in an institutional setting (105).
1.5. NURSES AS CONTRIBUTORS TO SAFER PRESCRIPTIONS
Studies have demonstrated associations between levels of nurse staffing and a
number of patient outcomes (108–111). Nurses are often the final barriers between 
the patient and dangerous situations such as medical errors (112). The nurse’s role 
as a safeguard has been examined in several studies; primarily in the intensive care 
setting (112–115). A report from the UK pointed out the positive correlation 
between the in patient to staff ratio and mortality in 14 NHS trusts that had 
performed below the general standard on mortality indicators (116). Exactly how 
nurses reduce mortality is not clear (117).
Nurses create medication errors as well as intercept them (23,75,77,113,118–120).
As described earlier, the medication process consists of prescribing, dispensing, 
administration, and monitoring. The physician’s and nurses’ responsibilities in the 
medication process are illustrated in Figure 1-1.
Occasionally, the medication process will be circular as the physician may alter the 
patient’s medication based on the nurse’s observations. Research into the 
identification of PIPs has so far been limited to elderly populations and almost 
exclusively carried out by pharmacists. However, nurses are expected to review 
prescriptions for correctness (is it what the physician prescribed?) before 
administering the medication. However, at this stage nurses are in a position to 
critically review the appropriateness of the prescription using the available 




Figure 1-1. The responsibilities of nurses and physicians across the medication process.
Source: own contribution.
1.6. NURSE-PHYSICIAN COLLABORATION IN PSYCHIATRIC IN-
PATIENT CARE
The NPC in psychiatry is largely unexplored. Studies, in settings other than 
psychiatry, demonstrate how a poor NPC adversely affects patient outcomes 
adversely by jeopardising the quality of care and patient safety, leading to increased 
mortality (121,122). It has been suggested that effective NPC might have a
significant positive impact on patient outcome (123).
Ineffective NPC has consequences for both nurses and physicians. Research shows 
how poor NPCs affects nurses, leading them to become increasingly dissatisfied 
with their jobs, wanting to leave and find occupation elsewhere (121,124).
Physicians described their frustration when orders were not carried out in a 
satisfactory manner or the communication between the two parties was unclear; 
they described this frustration as a major source of job dissatisfaction (121).
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An analysis of nurses and physicians collaboration in the stages of prescribing and 
administering medications revealed that when physicians and nurses do rounds 
together, the physician benefits from the nurse’s knowledge about the patient and 
the nurse possesses a better understanding of the patient’s medical case and the 
decision-making process behind each prescription (125). According to Reason, the 
well-known author of literature on human error, safety is about relationships –
which is about teamwork (54). Working in teams requires a levelling of hierarchy 
and mutual respect, based on good communication (13).
Disruptive behaviour from physicians or nurses is a poorly defined phenomenon but 
isgenerally understood as a hostile, intimidating behaviour characterised by poor 
communication. Though most research on the subject has focused on physicians, 
nurses may also display disruptive behaviour (126). Physicians, when displaying 
disruptive behaviour, tend to be direct and overt; for example shouting, acting 
offended and rolling their eyes. Nurses’ disruptive behaviour is often of a more 
passive-aggressive nature; for example being ‘backstabbing’, fault-finding and 
‘back-door undermining’ (126,127). NPC, whether disruptive or supportive and 
respectful, is thus an important factor in medication safety (124,126,127).
In this thesis, NPC is defined as:
‘Actions related to sharing information about patients, participating in decision-
making concerning patient care, and providing comprehensive care to patients 
from a patient-centred perspective.’ (128)
1.7. LITERATURE SEARCH
The databases Pubmed, the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) with full text and PsycINFO were searched to identify 
literature relevant to the four studies. Languages were restricted to English and 
Scandinavian. The databases were searched up to and including 2016. Where 
available, Medical Subject Headings (MeSH), and CINAHL Headings and Subject 
Headings were used. Alternatively, search terms were entered as free text. Limits 
were applied using “human participants” and no time restrictions were applied. The 
following search terms were combined in structured searches: 
‘safety’, ‘patient safety’, ‘medication safety’,
‘medication errors’, ‘adverse drug events’,
‘psychiatry’, ‘psychiatric’, ‘mental’, ‘mental health’,
‘nurses’, ‘psychiatric nursing’, ‘potentially






‘disruptive behavior’, ‘outcome’, ‘patient outcome’.
The search also included other sources: webpages of official authorities, health 
authorities, health organisations, and reference lists from relevant literature.
1.8. EXISTING LITERATURE AND LIMITATIONS
1.8.1. STUDY I (ERRORS IN THE MEDICATION PROCESS)
The latest review on medication errors in mental health settings concluded that the 
evidence was limited and also commented on the problems inherent in comparing 
the incidence and prevalence of medication error outcomes when methodologies 
vary (16). The most reliable and valid methodologies used, to study medication 
errors, have been scrutinised in several papers (41,45,48–52). Studies investigating 
errors, in all stages of the medication process in psychiatry are few and do not 
consistently rely on the most sensitive methods (17,129–131).
Some studies have focused on prescribing errors (132–138), and others on 
administration errors (77,136). The literature demonstrates that errors in the 
medication process are frequent, however, establishing the prevalence and
incidence and types of error are highly difficult (16,139). Moreover, medication 
errors in psychiatry do cause harm but tend to be less serious or fatal than in general 
hospital settings (17).
All studies retrieved from the literature search were from the US, UK, or Japan, and 
their applicability to Danish settings are unknown. 
To date, in psychiatry, there have been no studies of errors in all stages of the 
medication process using the most valid and sensitive methods. Moreover, in 
Denmark, no studies in psychiatry have focused on medication errors. 
Therefore, a cross-sectional study was designed to detect errors in all stages of the 
medication process. In line with the literature, the most appropriate methods for 
identifying errors were chosen in each stage of the medication process.
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1.8.2. STUDY II (CHARACTERISTICS OF PIPS)
Many studies point to PIP as a significant problem in the elderly causing 
unnecessary hospital admissions, increased morbidity and even mortality (140). The 
elderly are often at risk of PIP due to increased morbidity, complex medication 
regimens with many concurrent prescriptions and age-related changes in 
physiology, such as diminished renal capacity and changes in liver metabolism 
(36,90). Psychiatric patients do not necessarily share the elderly’s vulnerabilities. 
However, psychiatric patients have a life expectancy 15 – 20 years shorter than the 
general population – often due to somatic illness (141,142). Psychiatric patients 
also suffer challenges such as unpleasant side effects to their medication; examples 
being diabetes, obesity, hypercholesterolemia, and related morbidity such as heart 
disease (143–145). All of which emphasise the importance of appropriate 
medications for psychiatric patients. However, reports indicate that inappropriate 
prescribing defined by explicit categories such as antipsychotic polypharmacy, 
high-dose antipsychotics, and high-dose benzodiazepines are frequent and 
problematic (18,19,146).
To the best of our knowledge, the majority of studies reviewed so far, suffer the 
limitation of not considering the general psychiatric patient. When studies include 
general psychiatric patients, they do not consider the entire medication regimen for 
each patient but rather a defined category of inappropriate prescribing. 
Therefore, a cross-sectional study aiming to identify and describe PIP was 
undertaken.
1.8.3. STUDY III (NURSES AND PIP IDENTIFICATION)
Many nurse-led interventions have demonstrated a positive effect on a range of 
patient outcomes such as improving survival in patients with heart failure, reducing 
hypertension, controlling anticoagulant treatment, and the management of patients 
with lung cancer (147–151). Studies indicate that nurses beside improving 
psychiatric patients adherence also improve the assessment of individual needs and 
treatments (152–154). Previous research findings also report nurses positively 
participate in and improve pharmacovigilance; at least in Sweden (155–157).
Although nurses are involved in the multidisciplinary collaboration surrounding the 
medication process, only a few studies have investigated nurses capacity for 
systematically detecting and preventing medication-related problems (23,24,158).
These studies indicated that nurses were able to identify and respond to relevant
problems related to elderly patients’ medication. One small Japanese study has 
investigated nurses’ collaboration with physicians in managing medication in 
psychiatric care (154). This controlled interventional study demonstrated an 
improvement in schizophrenic patients’ social functioning as well as a number of
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other measures, when physicians changed medication after receiving reports that 
nurses perceived a change was necessary. However, the study suffered some 
limitations due to a retrospective design. Another study showed a positive impact of 
a medicines management course to nurses on patient outcomes (158). The study 
was designed as a randomised controlled trial, but assessed only the efforts of the 
nurses on patients’ adherence to medication and the consequently clinical outcome 
for the patients on the Positive and Negative Syndrome Scale (PANSS).
Therefore, an interventional, controlled study was undertaken, placing nurses 
centrally in identifying and reporting PIP after a pharmacology course, was
conducted in order to investigate nurses’ skills and potential improvements in 
prescribing quality.
1.8.4. STUDY IV (NURSE-PHYSICIAN COLLABORATION)
Before implementation of any patient safety practice, it is necessary to consider the 
context in order to evaluate the possibility of similar outcomes in different settings 
(159). If nurses’ observations and knowledge of patients’ unique situations are to 
lead to improvements in prescribing, NPC has to in place, as physicians have the 
primary responsibility for patients’ prescriptions. This raises questions about NPC 
in psychiatry, and particularly in relation to medication optimisation.
Evidence from general hospital settings suggests a positive correlation between the 
NPC and patient outcomes (122,124,126,160). I identified a few studies of NPC in 
psychiatric settings; this literature emphasised that a positive NPC is associated
with improved patient outcomes and fewer adverse events to patients and staff 
(154,161,162). Additionally, strong nurse-physician relationships as significantly 
associated with lower rates of psychiatric nurse burnout (163). However, there are 
few studies directly addressing the influence of NPC in medication optimisation in 
psychiatry.  
As a result, a qualitative study using focus groups was carried out to explore the 
perceptions and views of nurses collaborating with physicians on medication 
optimisation in a psychiatric hospital.
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CHAPTER 2. HYPOTHESES AND 
OBJECTIVES
The overall aim of this thesis was to investigate medication safety for psychiatric 
patients and nurses’ possible role in improving medication safety. Failing 
medication safety must be understood comprehensively and including errors in the 
medication process, medication errors, PIPs, and the views and perceptions of 
individuals. The four studies comprising this thesis all investigate an aspect of 
medication safety and together provide evidence for understanding the dimensions 
of medication safety, prescribing patterns, and nurses’ preventive and mitigating 
role in prescribing for psychiatric patients. 
I developed the following hypotheses and the adjacent objectives based on the 
previously described literature search.  
2.1. STUDY I (ERRORS IN THE MEDICATION PROCESS)
Hypothesis: Errors in the medication process in psychiatric hospitals are frequent 
and similar to the prevalence found in general hospital settings.
Objective: To evaluate the prevalence, types, and potential clinical consequences of 
errors in the medication process in psychiatric wards.
2.2. STUDY II (CHARACTERISTICS OF PIPS)
Hypothesis: Psychiatric inpatients experience PIPs at the point of admission, the 
presence of PIPs are associated with age, gender, alcohol- and substance abuse,
polypharmacy (more than five prescriptions) and somatic illness.
Objective: To evaluate the prevalence, types, and predictors of PIP as well as the 
severity of potential clinical consequences.
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2.3. STUDY III (NURSES AND PIP IDENTIFICATION)
Hypothesis: Nurses can identify PIPs in psychiatric patients’ medication lists and 
their reports to physicians lead to relevant changes to prescriptions. 
Objective: To examine the characteristics, magnitude, and potential effect of 
pharmacologically trained nurses’ systematic review of medication records on the 
appropriateness of prescribing for newly admitted psychiatric patients. 
2.4. STUDY IV (NURSE-PHYSICIAN COLLABORATION)
Hypothesis: Collaboration between nurses and physicians can be improved.
Objective: To explore how nurses perceive collaborating with physicians on 




The studies in this thesis all took place in the Psychiatric Department of Aalborg 
University Hospital, Denmark. The Psychiatric Department serves the entire North 
Denmark Region and is organised in two clinics: Clinic South and Clinic North. 
The North Denmark Region contains approximately 580,000 citizens, and every 
year the clinics receive close to 2,800 adults. The individual units specialise in 
acute psychiatry, bipolar disease and depression, psychotic illnesses, and 
personality- and anxiety disorders (164). This thesis is based on data from chart 
reviews (Study I), direct observation (Study I), medication reviews (Studies II & 
III), and focus group interviews (Study IV).
3.1. STUDY I (ERRORS IN THE MEDICATION PROCESS)
3.1.1. DESIGN
Study I was a descriptive, cross-sectional study of errors and potential harm in the 
medication process. This study included both regular and PRN prescriptions except 
in discharge summaries. Three different methods for collecting data were applied: 
direct observation, unannounced visits to the wards to collect dispensed drugs for 
identification, and chart review to detect the most reliable and valid estimates of 
errors in each stage of the medication process (48,49,51).
3.1.2. SETTING
Study I was carried out from January 2010 to April 2010 in three bed units in the 
Psychiatric Department, Clinic South, Aalborg University Hospital, Denmark.
3.1.3. STUDY POPULATION 
The observational unit involved any handling of medication (prescribing, 
dispensing, and administering medication). The study population investigated 
prescribing medication, nurses and nurses’ assistants dispensing and administering 
medication. There were no exclusion criteria applied. 
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3.1.4. DATA COLLECTION
Observation
Direct observation was used to identify errors in the dispensing and administration 
stages. One of the investigators (ALS) observed nurses and nurses’ assistants who 
dispensed and administered medications. The same investigator spent three eight-
hour shifts (two-day shifts and one evening shift) in each ward. The nurse or nurse 
assistant being observed had knowledge of the study’s purpose but was not 
informed about what observations were being registered. Observations of the 
dispensing or administering of drugs were registered on a structured paper form and 
compared to the prescriptions in the EMR to identify discrepancies. The 
investigator classified any discrepancy as an error which was categorised according 
to the error types outlined in Appendix A.
Unannounced visit
The unannounced visit served as an unbiased method to identify errors in the 
dispensing stage. The use of two methods in the dispensing stage, observation and 
unannounced control visits, was intended to validate the results from the 
observational part of the study. The unannounced visit was used to identify errors in 
the dispensing stage without the nursing staff being aware of an imminent check of 
their actions. One of the investigators (ALS) arrived unannounced to the bed units, 
approximately three weeks after the observational part of the study, and collected 
medication from the medication storage room after the dispensing had taken place, 
but before administration. The investigator followed up by identifying and 
comparing the dispensed medications (using an authorised webpage
(http://pro.medicin.dk/)) to the patient's prescriptions in the EMR. The investigator 
classified any discrepancy as an error and categorised it according to the error types 
outlined in Appendix A.
Chart review
Chart review was used to identify errors in the prescribing stage, including 
discharge summaries. One of the investigators (ALS) compared prescriptions in the 
EMR to the error types outlined in Appendix A. The investigator screened all 
prescriptions the first time a patient’s chart was reviewed; if the same patient’s 
chart was reviewed more than once only new or altered prescriptions were screened
for errors. Only errors in the communication of a prescription were included.
Assessing potential severity of errors 
The SCPPs assessed the severity of each error identified in the communicating of 
an error in the prescribing stage, as well as those in the dispensing and 
administering stages. Because of logistic issues, errors in discharge summaries were 
not assessed for potential severity. The SCPPs utilised a four-point scale (non-
significant, significant, serious, and fatal) first published by Lisby et al. (165) to 
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assess the potential severity of the errors and PIPs (see Appendix D for elaboration
of the categories of potential clinical consequences).
3.1.5. STATISTICAL ANALYSIS
A defined denominator was required to enable the calculation of proportions of 
errors (31). ‘Opportunities for error’ (omissions, mistakes, and/or conscious or 
unconscious rule violations) was chosen as this denominator. All data analysis was 
performed using Stata/IC versions 13.0 (Statacorp, College Station, TX, USA). 
Frequency tables were used to show prevalence, proportions of errors, and error 
types in the different stages of the medication process. Interrater reliability for the 
SCPPs’ evaluations of severity of potential clinical consequences was calculated 
when appropriate, using the kappa test.
3.2. STUDY II (CHARACTERISTICS OF PIPS)
3.2.1. SETTING
Study II was carried out from 1 September to 31 November 2013 in the Psychiatric 
Department, Clinic South, and Clinic North, Aalborg University Hospital, 
Denmark. 
3.2.2. DESIGN
Study II was a cross-sectional, descriptive study of PIPs, potential harm, and 
possible predictors of PIPs. The method of data collection comprised medication 
reviews by SCPPs.
3.2.3. STUDYPOPULATION
of any psychiatric condition. Exclusion criteria were terminally ill patients with an 
anticipated short life expectancy, dual admissions to hospitals other than 
psychiatric, non-obtainable medical records, and no prescriptions. Forensic patients 
and child/adolescent patients were not included.
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3.2.4. DATA COLLECTION
Medication review
Two SCPPs (LPN and BKP) carried out all medication reviews following a
procedure adapted from a Danish Ph.D. thesis (166) in which medication reviews 
by clinical pharmacologists also played a role. The procedure is illustrated in Figure 
3-1.
Figure 3-1. The process of medication reviews by clinical pharmacologists. Adapted from 
‘Potentially inappropriate prescriptions in patients admitted to psychiatric hospital’, Nordic 
Journal of Psychiatry, copyright © Nordic Psychiatry Association. Reprinted with
permission from Taylor & Francis Ltd, www.tandfonline.com on behalf of the Nordic 
Psychiatry Association.
The original procedure devised by Bonnerup et al. (166) included patient 
involvement and recommendations for ward physicians, but these were excluded in 
the present study. The SCPPs categorised all identified PIPs. The 14 categories can 
be seen in Appendix B. Additionally, the SCPPs carried out an assessment of 
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severity of each PIP identified in the decision-making stage of prescribing. For the 
assessment of severity of the PIPs, the SCPPs utilised the same method described 
under Study I, Section 3.1.4.
3.2.5. STATISTICS
In Study II, frequency tables were used to show the prevalence, categories, and
potential clinical consequences of PIPs as well as the characteristics of the patients 
in the study populations. A logistic regression model was used to identify potential 
predictors of PIPs. The model predicted the odds of having versus not having one or
more PIP and was adjusted for age, gender, alcohol or substance abuse, the number
of prescriptions and somatic illness. The results are presented as odds ratios (OR) 
with 95% confidence intervals (95% CI). Statistical significance was set at an alpha 
level of 0.05. All analysis of data was performed using Stata/IC version 14.0 
(Statacorp, College Station, TX, USA).
3.3. STUDY III (NURSES AND PIP IDENTIFICATION)
3.3.1. SETTING
Study III was carried out from 1 November 2014 to 30 June 2015 in the Psychiatric 
Department, Aalborg University Hospital, Denmark. Two bed units served as 
intervention units and two bed units as control units, from Clinic South and Clinic 
North, respectively.  
3.3.2. DESIGN
Study III was a controlled, interventional before-and-after study investigating the 
potential effect of pharmacologically trained nurses’ systematic reviews of 
medication records, on the reduction of PIPs for psychiatric patients at the point of 
admission. Patients in the control bed units received ‘care as usual’ throughout the 
study. ‘Care as usual’ included physicians carrying out a medication review in 
addition to examining the patient. Patients in the intervention bed units also 
received ‘care as usual’, but in addition to this, nurses who had attended a 
pharmacology course reviewed the patients’ medication records. If the nurses 
identified what they perceived to be a PIP, they would present their observation to a 
physician who would then decide on any further action. SCPPs carried out 
medication reviews on all patients included in the study from start to finish. The 
SCPP-led medication reviews provided a baseline period (the before) to compare 
any changes or differences during the intervention period (the after) both within and 
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across the control and intervention bed units. Additionally, the SCPP-led 
medication reviews provided a ‘gold standard’ against which the nurses’ 
identifications of PIPs was validated. A description of the methods of medication 
reviews, the nurses’ pharmacology course, and the recording of the nurses’
observations is found in Section 3.3.4. Figure 3-2 illustrates the study design. Bed 
units were selected based on matched age categories and diagnoses to ensure 
comparability across control and intervention bed units. 
Figure 3-2. Illustration of the study design.
Source: own contribution.
3.3.3. STUDY POPULATION
Study III included all adult patients admitted due to any psychiatric condition.
Exclusion criteria were terminally ill patients with an anticipated short life 
expectancy, an expected length of stay of less than 48 hours, patients transferred 
from another psychiatric unit or who had previously been included in the study, and 
eligible patients where the nurses failed to review the medication list.
3.3.4. DATA COLLECTION
Medication reviews 
Two SCPPs (LPN and BKP) carried out all medication reviews which followed the 
same procedure as in Study II (see Section 3.2.4 and Figure 3-1). The original
procedure presented by Bonnerup et al. included patient involvement and 
recommendations for ward physicians, but this was excluded in Study III in this 
present thesis. The SCPPs categorised all identified PIPs according to type (see 
Appendix B). In Study II, the SCPPs utilised 14 types of PIPs which were changed
to 15 types of PIPs in Study III. In Study II ‘omission of Therapeutic Drug 
Monitoring (TDM))’ was classified as ‘other’; but it became evident that valuable 
information could be gained by isolating ‘TDM’ from ‘other’ resulting in 15 types 
of PIPs in Study III. In Study III, the SCPPs carried out medication reviews during 
baseline (the ‘before’) and the intervention period (see Appendix C for the paper 
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form used by the SCPPs to record their medication reviews). For the assessment of 
severity  of  the PIPs, the SCPPs utilised the same method as described under Study
I, Section 3.1.4
3.3.5. THE INTERVENTION – A PHARMACOLOGY COURSE AND 
NURSES’ SYSTEMATIC OBSERVATIONS 
The pharmacology course
Before the testing of the intervention, all nurses from the intervention bed units 
received a five-day course on general pharmacology and psychopharmacology. The 
course also included treatment principles for some of the major mental disorders, 
principles of medication review, exercises in identifying PIPs, and how to register 
systematic observations. The course programme can be seen in Appendix E.
Classes given at the course were delivered by the SCPPs (BKP and LPN), who also 
performed all the medication reviews alongside the nurses in the intervention, but 
lecturers also included psychiatrists, physicians, a pharmacist and the course leader 
(ALS).
Nurses collecting observations of PIPs
After the pharmacological course, the intervention was initiated. Patients were 
included consecutively in the order they were admitted to the bed unit. As soon as 
possible, after the patient had been examined by a physician, the nurses would 
critically review the patients’ medication list, using their experience, skills learned 
during the pharmacology course, and any additional knowledge they might have 
acquired about the patient's situation. All observations of what the nurses 
considered a PIP were recorded on a paper form (see Appendix F).
3.3.6. STATISTICS
In Study III, frequency tables were used to show the prevalence, categories, and 
potential clinical consequences of PIPs, as well as the characteristics of the patients 
in the study population. To detect an absolute reduction of 20 percentage points in 
patients receiving at least one PIP, at a two-sided 0.05 significance level, a sample 
size of 100 patients per group during the intervention period was needed to ensure 
80% power. The power calculation was based on findings in Study II (167) and a 
reduction of 20 percentage points was considered clinically relevant. Interrater 
reliability between the SCPPs’ and nurses’ assessments of whether or not a patient 
had at least one PIP was calculated using the kappa test. Difference in means was 
compared using the Wilcoxon rank sum test due to non-parametric data. Both linear 
and logistic regression analyses were applied to estimate a difference-in-difference 
(DID) between intervention and control bed units for the mean number of PIPs per 
-in-difference 
represents the coefficient for the interaction between intervention and control bed 
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units, and time (before/after). Data analysis of data was performed using Stata/IC 
version 14.0 (Statacorp, College Station, TX, USA).
3.4. STUDY IV (NURSE-PHYSICIAN COLLABORATION)
3.4.1. SETTING
Study IV was carried out at The University College of North Jutland, Denmark. The 
first focus group was assembled 21 December 2014 and the second focus group was 
assembled 5 January 2015.
3.4.2. DESIGN
Study IV comprises a qualitative focus group study. Two focus group interviews 
with nurses were carried out. The focus groups mixed participants from both 
participating bed units. Focus group interviews was the approach because the aim 
was to uncover aspects of collaboration between healthcare professionals and thus 
involved groups (168). More specifically, the aim was to explore the nurses’
perceptions of collaborating with physicians on medication optimisation in 
psychiatric bed units; this involves rules and values within and between professions 
and groups. These complex systems of collaboration might depend on local 
characteristics and cultures which was the reason for including nurses already 
familiar with each other, even though focus groups usually consist of individuals, 
who do not know each other (169). However, the design of the study also allowed 
for nurses not familiar with each other to engage. This choice of ‘mixing the bed 
units’ was developed to investigate social processes and possibly group interactions 
that would stimulate certain ideas or perhaps communication suppressed by the 
group (170).
Preparation for Study IV included a pilot test of the structured interview guide.
Participants were nurses from an acute psychiatric bed unit who frequently 
collaborated with nurses from the two bed units participating in the present study. 
The pilot test did not prompt any significant changes to the interview guide.
3.4.3. STUDYPOPULATION
The study population included all nurses who had previously participated in a 
mandatory five-day long training programme on general pharmacology, 
psychopharmacology, and medication safety. The nurses came from bed units 




In Study IV, the approaches used to collect data were a semi-structured interview 
guide, audio and video recordings, and field notes. The semi-structured interview 
was guided by the following themes:
Experiences and thoughts of collaborating with physicians about patients’ 
medications.
Self-perceived influence on NPC about medication optimisation and 
factors modifying this.
Nurses’ thoughts and perceptions of their needs for pharmacological 
knowledge and their possibilities for advocating safer medication of 
patients within the NPC.
The interviews were planned to last 60-90 minutes. The interviews took place 
immediately after the nurses completed the pharmacology course described under 
Study III (see Section 3.3.5). Before the interviews, the participants, and the 
interviewer had established a relationship during the pharmacology course, and the 
participants were aware of the interviewers’ areas of interest such as medication 
safety, nursing, and mental health. However, the interviewer took extensive
measures not to share or disseminate any personal or professional opinions during 
the pharmacology course. All efforts were aimed at establishing an environment 
that encouraged speaking and interaction between the nurses without restrictions. 
Only participants and the interviewer were present during the focus groups. Each 
focus group began with a relatively broad approach, making it possible to discuss a 
variety of nursing-related issues. The interviewer then moved on to the semi-
structured interview guide which was designed to unveil the respondents’
experiences, thoughts, and perceptions, both positive and negative.
The interviews in Study IV were recorded with a digital camcorder and a digital 
audio recorder to ensure two modalities of data in cases of uncertainty. The 
interviewer (ALS) transcribed all recordings. All transcribing was checked by an 
independent researcher not related to the project in any way, to check for 
consistency with both audio and video recordings.
The interviewer wrote field notes immediately after each focus group that 
documented her observations of moods, tendencies, and insights.
3.4.5. THEMATIC ANALYSIS 
Data analysis in Study IV was carried out in NVivo 11. The qualitative analysis 
applied to data involved inductive thematic analysis (171). The analyses were 
performed in four steps. Firstly, ALS repeatedly read the transcripts, searching for 
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meaning and inspiration for incipient coding. Secondly, these initial codes and
selected field notes were presented to and discussed with other researchers involved 
in the study until an agreement was reached on relevant codes. Thirdly, ALS 
continued to form themes from the coded data, and finally, the themes were 
reviewed until an agreement on the accuracy of themes was reached. The analysis 
followed the Consolidated Criteria for Reporting Qualitative studies whenever 




Figure 3-3 gives an overview of study designs and methodologies used in this 
thesis.
Figure 3-3. Overview of study design and methodology of the studies on which the thesis is 
based.
Source: own contribution.
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The studies in this thesis did not require permission from The Danish Scientific 
Ethics Committee as patient contact was not involved. 
The following approvals were acquired before initiating the studies:
Study I: was approved by The Danish Data Protection Agency (record number: 
2009-41-4215) and the hospital management. Participating staff were informed of 
the study’s purpose. 
Study II: was approved by the Danish Health and Medicines Authority (record 
number: 3-3013-118/1/), The Danish Data Protection Agency (record number: 
2012-41-0369), and the hospital management.
Study III: was approved by the Danish Health and Medicines Authority (record 
number: 3-3013-118/1/), The Danish Data Protection Agency (record number: 
2012-41-0369), and was registered with clinical.trials.gov (record number: 
NCT02052505). Participating staff were informed of the study’s purpose. 
Study IV: was approved by the hospital management and participation was 





The following sections describe the main results from the four studies upon which 
this thesis is constructed. Appendices at the back of the thesis contain additional 
material relevant to the results. 
5.1. STUDY I (ERRORS IN THE MEDICATION PROCESS)
The analysis in Study I included 67 patients; 24 (36%) men and 43 (64%) women. 
The mean age was 46 (IQR; 20-79) and the most common psychiatric disorder at 
admission was schizophrenia 22/67 (33%). Second most frequent psychiatric 
disorder at admission was bipolar disorder 11/67 (16%).
5.1.1. FREQUENCY OF ERRORS AND ERROR TYPES
Overall, 189 errors in 1082 opportunities for error were identified, generating an 
error rate of 17%. Table 5-1 presents frequencies of errors in the different stages of 
the medication process. 
Table 5-1. Frequency of errors in the different stages of the medication process. (Reprinted 
from Risk Management and Healthcare Policy, Volume 6, Soerensen AL, Lisby M, Nielsen 
LP, et al.,'The medication process in a psychiatric hospital: are errors a potential threat to 
patient safety?', p.23-31, copyright (2013), with permission from Dove Medical Press Ltd.)
Notes: Ntotal = the total number of opportunities of errors in each stage (prescription and doses); n, the 
total number of detected errors in each stage of the medication process. The difference in number of 
dispensed medications and administered medications in the observational study was due to incidents 
where staff had administered medicine without the investigators presence.















10/267 (4) 9/324 (3) 9/67 (13) 142/340 (42) 19/84 (23)
The highest proportion of errors was found in the administration stage 142/340 
(42%) followed by discharge summaries 19/84 (23%). The leading error type in the 
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administration stage was lack of identity control 135/142 (95%). Nine errors in 
discharge summaries were eligible prescriptions in the Computerised Physician 
Order Entry (CPOE), which was not extended to the discharge summaries. In the 
discharge summaries, where 19 errors were identified, the most frequent error type 
was ‘drug prescription’ 9/19 (47%) and ‘omission of drug’ 9/19 (47%). ‘Drug 
prescription’ includes errors in writing of a prescription, e.g. strength per unit, route 
of administration, form of administration, dose, frequency of administration, 
signature, date, and duration of treatment.
Two methods, observation and unannounced visit, were used to investigate the 
dispensing stage, generating a proportion of errors of 9/324 (3%) and 9/67 (13%), 
respectively. In the dispensing stage, the most frequent error type identified through 
observation was ‘lack of correct labelling’ (4/9), whereas the most frequent error 
type identified through unannounced visit was ‘omission of dose’ (6/9). ‘Lack of 
correct labelling’ means that all drugs administered to patients must be marked 
with the patient’s identity. Most errors in the unannounced control visit were 
associated with one nurses’ assistant.
The prescribing stage presented the lowest proportion of errors, 10/267 (4%) and 
the most frequent error type was ‘omission of PRN dosing’ in the CPOE (8/10). 
5.1.2. POTENTIAL CLINICAL CONSEQUENCES
Analysis of the assessments of potential clinical consequences applied a worst case 
scenario; if the clinical pharmacologists disagreed on the severity of an error, the 
most severe assessment was recorded for the analysis. The clinical pharmacologists 
did not assess errors in discharge summaries; thus the number of opportunities for 
error was reduced to 998 in the analysis of potential clinical consequences. 
Definitions on the rating of potential clinical consequences are outlined in 
Appendix D.
Interrater agreement for potential clinical consequences of errors in the prescription 
stage, errors in the dispensing stage in the observational part of the study, errors in 
the dispensing stage investigated with unannounced visit, and the administration 
stage, varied from good to perfect (0.54; 0.75; 0.82 and 1.0, respectively). The 
clinical pharmacologists assessed 84/998 (8%) opportunities for error as potentially 
serious or potentially fatal. Thus, according to the applied definition, medication 
errors were identified in 8% of all opportunities for error throughout the medication 
process.
As mentioned above, most errors were found in the administration stage and
approximately half of these errors, 73/142 (51%) were assessed to have potentially 
serious clinical consequences for patients. There were four potentially fatal errors in 
total. Two errors concerned ‘omission of PRN regime’ in the prescribing stage and 
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the remaining two errors were of the type ‘lack of identity control’ in the 
administration stage.
5.1.3. DRUG CATEGORIES
The most frequent drug categories related to potentially harmful errors were 
atypical antipsychotics, anxiolytic-sedative drugs, and mood stabilisers. Errors 
assessed as potentially fatal were found in the prescribing and administration stages 
and involved analgesics (opioids) (n=2) and atypical antipsychotics (n=2). Drugs 
related to somatic illness and with the potential for harming patients accounted for 
almost one in ten, 7/77 (9%), and predominantly involved anti-inflammatory and 
anti-rheumatic drugs.
5.2. STUDY II (CHARACTERISTICS OF PIPS)
This study included 207 patients. The mean age was 42 years with range 18-83. 
Schizophrenia and other psychotic disorders were the most frequent diagnoses at 
77/207 (37%), followed by affective disorders 68/207 (33%). Somatic illness 
affected little more than a third, 71/207 (33%), of all included patients. The leading 
categories of somatic disease were cardiac disease, diabetes mellitus 2, and COPD.
5.2.1. POTENTIALLY INAPPROPRIATE PRESCRIPTIONS
Overall, 349 PIPs were identified in 1291 prescriptions. The median number of 
prescriptions was four but, nonetheless, 26/207 (13%) patients in the study 
population were prescribed ten or more regular drugs daily. The proportion of 
patients with at least one PIP reached 123/207 (59%). The proportion of patients 
with at least one PIP assessed to be potentially harmful was 69/207 (33%) which is 
higher than the proportion of patients with at least one PIP assessed to be 
potentially fatal 24/207 (12%). Table 5-2 illustrates categories, frequencies, and 
severities of potential clinical consequences.
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Table 5-2. Categories, frequency, and potential clinical consequences of potentially 
inappropriate prescriptions (PIPs). (Reproduced from ‘Potentially inappropriate 
prescriptions in patients admitted to psychiatric hospital’, Nordic Journal of Psychiatry, 
copyright © Nordic Psychiatry Association, reprinted by permission of Taylor and Francis 













PIP N % N % N % N % N %
Interaction 
between drugs
125 36 2 1 42 34 49 39 32 26
Drug dosage too 
high




46 13 26 57 11 24 8 17 1 2




32 9 1 2 12 38 16 50 3 9




16 5 1 6 7 44 8 50 0 0
Inappropriate 
dosing interval
11 3 6 55 4 36 1 1 0 0
Drug dosage too 
small
8 2 0 0 6 75 1 13 1 13
Allergy 6 21 3 50 1 17 0 0 2 33
Duplicate drug 4 1 0 0 2 50 25 1 25 25
Inappropriate 
dosage time
3 1 1 33 2 67 0 0 0 0
Inappropriate 
dosage form








0 0 0 0 0 0 0 0 0 0
Total (N) 349 56 125 123 45
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Table 5-3 displays the logistic regression analysis of factors possibly predictive of 
PIPs.
Table 5-3. Characteristics of patients prescribed potentially inappropriate prescriptions 
(PIPs) versus those not perscribed PIPs (N=207). (Reproduced from ‘Potentially 
inappropriate prescriptions in patients admitted to psychiatric hospital’, Nordic Journal of 
Psychiatry, copyright © Nordic Psychiatry Association, reprinted by permission of Taylor 
and Francis Ltd, www.tandfonline.com on behalf of Nordic Psychiatry Association.)   
The reference group is the category to which all other categories are compared for each variable. CI: 
confidence interval; OR: odds ratio. The OR reflects the association between the odds for at least one 
PIP and the interaction of each variable. aAdjusted for age, gender, substance abuse, number of 
prescriptions, and number of somatic diagnoses using logistic regression considering each patient as a 
cluster (N=207).









Age (reference group: 40-59)
18-29 years 29 (46) 34 (54) 0.66 0.30-1.44 0.296
30-39 years 26 (68) 12 (32) 1.45 0.59-3.61 0.418
40-59 years 24 (33) 49 (76) 1
24 (73) 9 (27) 0.77 0.29-2.06 0.602
Gender (reference group: male)
Male 54 (57) 41 (43) 1
Female 74 (66) 38 (34) 1.44 0.75-2.76 0.273
Alcohol or substance abuse 
(reference group: no alcohol or 
substance abuse)
No substance abuse 88 (63) 52 (37) 1
Substance abuse 40 (60) 27 (40) 1.16 0.55-2.42 0.702
No. of prescriptions (reference 
group : 1-5)
43 (43)
1-5 prescriptions 85 (79) 57 (57) 1
66 (51) 22 (21) 3.66 1.88-7.11 <0.0001
No. of somatic diagnoses 
(reference group: 0)
62 (79)
0 somatic diagnoses 63 (49) 1
16 (21) 2.53 1.17-5.48 <0.018
Pseudo R2 0.15
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Only polypharmacy (>5 prescriptions) and having one or more somatic diagnoses 
affected the risk of PIPs. No other variable appeared as an important confounder or 
predictor of PIPs.
When performing subgroup analysis where potentially severe and potentially fatal 
PIPs were analysed together, patients with polypharmacy (>5 prescriptions) had a 
more than doubled risk of potentially harmful PIPs (RR=2.42, 95%CI=1.64 – 3.56) 
compared to patients receiving <5 prescriptions. A comparison of patients with 
somatic diagnoses and patients without somatic diagnoses yielded an almost twice 
as high relative risk (RR) of potentially severe or potentially fatal PIPs (RR=1.96, 
95%CI=1.41-2.72). Antipsychotics were the unconditionally most prevalent drug 
category associated with the potentially serious or potentially fatal PIPs. 
Antipsychotics and antidepressants were the most frequent drug categories 
associated with potentially serious and potentially fatal PIPs. However, drugs used 
to treat somatic conditions were also associated with potentially serious and 
potentially fatal PIPs. Some examples are non-steroidal anti-inflammatory drugs
(NSAIDS), antibiotics, and beta-blockers.
5.3. STUDY III (NURSES AND PIP IDENTIFICATION)
The study included 396 patients. The median age was 43 with an interquartile range 
of 30-56. The primary psychiatric disorder was schizophrenia (and other psychotic 
disorders). There was substantial comorbidity with 123/396 (31%) of the patients 
having one or more somatic conditions. The most frequent comorbidity was cardiac
disease. There were no notable differences across the participating bed units 
indicating a successful selection of bed units that matched regarding patient 
diagnosis and age categories.
5.3.1. POTENTIALLY INAPPROPRIATE PRESCRIPTIONS
The SCPPs reviewed 396 patients and 2625 prescriptions comprising 1894 regular 
prescriptions and 758 PRN prescriptions. The medication reviews by the SCPPs 
showed that 66% (262/396) of the patients were prescribed at least one PIP. 
Table 5-4 shows the primary outcomes of the scenario of potential improvement 
had all PIPs identified by SCPPs and nurses, received the relevant alterations. There 
was not a statistically significant DID in the mean number of PIPs per patient, 
between the control and intervention bed units. Additionally, the potential reduction 
intervention bed units was not a statistically significant reduction. There was almost 
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no variation in the proportion
when comparing the baseline period and the intervention period.
Nurses’ identifications of PIP
The nurses in the study reviewed 121 patients who were prescribed 756 
prescriptions, consisting of 548 regular prescriptions and 208 PRN prescriptions.
Table 5-4. Potential improvements in number of potentially inappropriate prescriptions 






































38 (65.5) 65 (53.7) 0.61 (0.32-1.17) 0.14
Control bed 
units








Differences in means were compared using a Wilcoxon rank sum test, and differences-in-difference 
was estimated with a linear regression model.
Odds ratios for the intervention and control bed units comparing before-and-after was estimated 
using logistic regression and difference-in-difference was estimated by the OR for the coefficient for 
interaction between groups (intervention bed unit/control bed unit) and time (before/after) in a 
logistic regression model.
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The nurses identified 51% (62/121) of patients as having one or more PIPs with a 
moderate interrater reliability between nurses and SCPPs. The overlap between the 
nurses and the SCPPs’ identifications of PIPs totalled 38 PIPs equalling 17% of the 
SCPPs’ identifications of PIPs. The nurses identified 13 potentially serious and five 
potentially fatal PIPs in the ‘interaction between drugs’ category. In total, they 
identified 38% (24/64) of all PIPs identified by the SCPPs in the ‘interaction 
between drugs’ category. The nurses’ second most common finding was ‘omission
of indication’ (n=20), overlapping with only four PIPs (13%) identified by the 
SCPPs in the same category. When only PIPs overlapping with SCPPs’ assessments
were included, potentially fatal PIPs were identified in the categories ‘interaction 
between drugs’ (n=5) and ‘interaction between drug and disease’ (n=1).
Secondary outcomes
Physicians altered or wrote prescriptions for 25 patients in response to nurses’ 
observations. The nurses’ observations covered 11 categories of PIP and the 
physicians altered or wrote prescriptions in 10 of the 11 categories. The physicians 
altered or wrote most prescriptions in the category ‘interaction between drugs’ and 
‘omission of indication for treatment’. Only in the category ‘interaction between 
drugs’ did the physicians alter prescriptions assessed to be potentially harmful by 
the SCPPs. The proportion of PIPs altered or written by physicians in response to 
nurses’ observations during the intervention was 34% (95%CI 26.4-42.9). Only 
17% (95%CI 7.6-30.8) of the PIPs identified by nurses and responded to by 
physicians, were also PIPs identified and assessed for severity by the SCPPs. 
5.4. STUDY IV (NURSE-PHYSICIAN COLLABORATION)
5.4.1. THEMES AND SUBTHEMES
The thematic analysis of the focus groups revealed three themes which were
divided into subthemes, as illustrated in Table 5-5. The themes covered both 
barriers and promoters for NPC, and also the circumstances with potential for being 
both a barrier as well as a promoter (named ‘Janus circumstances’ after the two-
faced Roman God).  
Barriers to nurse-physician collaboration
The feeling of not being heard
Specific barriers mentioned by nurses were of an emotional character, for example 
the feeling of being ignored and not heard resulting in resignation to the situation. 
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Table 5-5. Themes and subthemes.
Theme Subtheme Supporting quotes
Barriers to NPC The feeling of not 
being heard
When I tried to question something, I would not get 
very far. They (the physicians) are rarely rude. They 
just sort of ignore you and then I withdraw from 
commenting on medications (a couple of other nurses 
broke in and supported this view by saying they had the 
same feeling) – Focus Group 2, Participant 1
Disputes between 
physicians
Sometimes the nurses get caught in the middle if 
physicians disagree on the medication and then it is
easy to lose the general idea of what to observe and 






When physicians review the medication before 
discharge and take the initiative to involve us, and we 
talk and review together…the nurses will often be able 
to tell something extra about the patient’s use of 
medication which is not described in the patient record 
– Focus Group 2, Participant 2
Access to physician Whenever I get the chance to speak to the physician
myself, I will. I get a much better understanding of the 
patient’s entire medical situation, and the physician 
receives updated information about the patients’ 
medications. The patients talk to us [nurses] in a 
different way, and I can better help the patients express 
their experiences and needs when we are all there. It is
the best way – Focus Group 1, Participant 9
The Janus 
circumstances: 





The culture is so different between physicians and 
nurses [in psychiatry]. However, you let yourself be 
lulled into apathy here. I do not think too much about it 
anymore, but it used to bother me terribly, that so many 
patients had somatic comorbidity and it received next to 
none attention – Focus Group 1, Participant 3
The way rounds are 
organised
1. It offers more responsibility and more ownership 
when you go rounds on your own patients and discuss 
whatever is relevant for the patients’ medication 
regime. The information you can offer the physician 
becomes more nuanced – Focus Group 1, Participant 8
2. The person who walked the ward round had not seen 
that the patient used ibuprofen, had abdominal pain, and 
black stools  - and any assistant knows that black stools 
and low haemoglobin equals a phone call to the 
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physician – and, well, it went terribly wrong – didn’t it? 
[addressing colleagues from her own ward]. The way 
we go rounds is antiquated’. – Focus Group 2, 
Participant 1




1. If we want to do more of this… recognising when the 
medications are doing the patients no good… we need 
annual courses like we have on handling conflicts and 
cardiac arrest – Focus Group 2, Participant 1
2. I mean, if the medication is a problem, it was created 
by the prescribers. The monkey should not be passed
onto the nurses - Focus Group 2, Participant 3
Disputes between physicians
In addition, encounters involving disagreements between physicians were described
as barriers which influenced the nurses’ ability to focus on effects and side effects 
of patients’ individual pharmacotherapies. The disputes between physicians about 
patients’ medications left nurses worried that medication safety was jeopardised
through non-systematic observations.
Promoters for NPC
Physicians inviting nurses to collaborate
Promoters for NPC described by the nurses involved experiences where physicians 
had initiated collaboration and took initiative to discuss medication plans. The 
nurses linked ‘good communication’ in the NPC with including the nurses’ 
observations and opinions in the conversation. Concurrently, the nurses described 
how physicians who were explicit in their expectations and appreciation within the 
NPC added positively to the nurses’ professional competencies, as well as their job 
satisfaction. 
Access to a physician
Being able to talk to and discuss medications directly with a physician was 
described by the nurses as providing an opportunity to learn about medications and 
pharmacotherapy from the physician. Access to the physician was also seen by the 
nurses as a way to increase knowledge about medication and treatments to improve 
the broader management of treatment and care for the patients.
The Janus circumstances: can be both barriers and promoters
Having experience from somatic care
Nurses with extensive experience in medical, surgical and intensive care unit 
settings expressed two perspectives on NPC. Firstly, there was the perception that a 
reluctance to address somatic issues in psychiatry curbed their opportunities to use 
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their experience actively in the clinical setting. Secondly, the somatic experience 
was also seen as a qualification that could facilitate more holistic patient care. 
The organisation of ward rounds
The nurses saw ward rounds as a necessity and important for the NPC, however, the 
framework within which the ward rounds were processed in the two bed units 
sparked different views. One ward had organised their ward rounds so that 
physicians would seek out the contact nurse and they would see the patient together. 
This was, without exception, seen as a propitious procedure. The other unit had 
organised their ward rounds so that one senior nurse, usually the same one, handled 
the ward round with the physicians, and the nursing input consisted of notes from
the nurses on the floor to this senior nurse about what the physician needed to 
attend to. All nurses from this bed unit considered this type of ward round 
unsuitable in contemporary nursing. A few nurses also remarked that it produced a 
feeling of hierarchy between the nurse doing rounds and nurses on the floor.
The way nurses perceive their own medication competencies
All nurses perceived their medication competencies as insufficient and there was a 
general aspiration to improve their knowledge of pharmacology and medication 
optimisation. One nurse suggested a formal approach similar to annual courses 
already in place at the hospital in which the nurses were employed. The nurses also 
saw their role as central to the patients’ medication adherence as well as in offering 
support and advice in situations where the patients had questions about medication 
or were reluctant to take the prescribed medications. However, the nurses also saw 
room for improvement in their counselling of patients, due to their lack of 
knowledge. All nurses agreed with, and consistently encompassed the act of 
observation of effects and side effects as part of nursing. Nevertheless, there was 
also hesitancy among some of the nurses in taking on medication optimisation 






This thesis investigated errors in the medication process, PIPs, nurses’ potential for 
reducing the prevalence of PIPs, and finally nurses’ perceptions of collaborating 
with physicians on medication optimisation in psychiatry. 
The findings contribute to knowledge about errors in the medication process in 
psychiatric bed units. The study concluded that patients in psychiatry, during the 
medication process, are exposed to errors in to a degree similar to that found in 
somatic hospitals. Additionally, the potential clinical consequences for psychiatric 
patients are serious and similar to those identified by researchers in somatic 
hospitals. 
PIPs are also frequent and affect more than half of all psychiatric patients admitted 
to psychiatric hospital. A significant proportion of PIPs has the potential to harm 
patients and in some cases may even prove fatal. Drug-drug interactions were the 
main category of PIPs. The findings also indicated somatic illness and 
polypharmacy as risk factors for PIPs.
Nurses might be an unrecognised resource in preventing and mitigating PIPs in 
terms of what PIPs the nurses identify and report to physicians and to what extent. 
However, the study also demonstrated that PIPs changed by physicians based on 
nurses observations not necessarily correspond with the findings of PIPs by SCPPs 
in the same population. The effect of the nurse-led intervention was limited and not 
statistically significant when comparing results before-and-after. 
The characteristics of NPC, from the nurses’ perspective, partially explain the 
limited effect of nurses identifying and reporting PIPs. Nurses described barriers, 
promoters and certain circumstances in which both negative and positive outcomes 
was a possibility. Barriers included the individual nurse's feeling of not being heard 
and doubt in the correctness of medications as consequence of physicians’ 
disagreements. Promoters included physicians actively engaging in collaboration 
and the nurse having an actual possibility of reviewing the patient together with a 
physician. The ambiguous circumstances involved, among other, when nurses had
somatic experience. The nurses described somatic experience as either favourable 
or as a source of frustration rooted in feeling helpless due to a perception, on the 
part of the nurses, of a disinclination to treat physical illness in psychiatric 
hospitals. The ambiguous circumstances also included the organisation of rounds on 
the bed units as well as the nurses’ self-perceived medication competencies.
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6.2. COMPARISONS WITH EXISTING LITERATURE AND
METHODOLOGICAL CONSIDERATIONS
6.2.1. STUDY I (ERRORS IN THE MEDICATION PROCESS)
There were errors in 17% of all opportunities for error and trying to compare this 
error rate with existing literature will, at its best, be limited. Depending on the study 
question, the numerator can be an event or a time interval where the event or time
interval in question also varies. Some examples from psychiatry are: 6.22 self-
reports of error per 1000 patient days (all stages in the medication process) (17), 5.5 
per month (all stages in the medication process) (131), 0.024 per prescription (the 
prescribing stage) (135), 0.82 per patient (132). These estimates do not allow direct 
comparisons. 
Errors in the administration stage were the most frequent error type. Only a few
studies have investigated administration errors in psychiatry. In this present study, 
administration errors constituted 142/340 (42%) of all errors. The relatively high 
proportion of administration errors is in contrast to other studies, as one study 
reported 10% of all medication errors as administration errors and another study of 
elderly psychiatric patients reported 25.9% of all errors as administration errors 
(77,131). Although the same denominator was chosen in the aforementioned 
studies, e.g. opportunities for error, the variation is most likely due to differences in 
error types in the administration stage and local guidelines on the administration of 
medication. Of all errors in the administration process, the clinical pharmacologists 
assessed 51% as potentially serious and 1% as potentially fatal. This is in contrast 
to Haw et al., who assessed that approximately 15% of identified errors in the 
administration stage had the potential for harming patients (77).
Discharge summaries comprised 10% (19/189) of all errors in the study. This 
finding cannot be compared directly to other studies due to methodological 
differences. However, in earlier studies, the correctness of discharge summaries has 
been poor (172) and rates of error up to 36% and 41% have been stated (165,173).
A Danish study also applying unannounced visits as a method of data collection 
stated that surgery and psychiatry had the highest rates of dispensing errors. This 
present study applied two methods showing a 10% difference in the proportion of 
error. It is possible that the two different error rates in the dispensing stage in this 
present study (9/324 (3%) and 9/67 (13%)) stemmed from the two different 
methods of detecting errors in that stage, but most likely from a dependency in data 
which arose from the few nurses and nurses’ assistants participating. Other studies,
have found error rates ranging from (75,165).
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In this present study, an error was identified in 4% of all opportunities for error in 
the prescribing stage. However, only the communicating (writing) of a prescription 
and not the decision-making related to the prescription - was included. As with all 
other measurements of prevalence in the medication process, the prescribing stage 
is challenged. Nonetheless, our finding is supported by a systematic review from 
2009 where a median error rate of 7% was established (174). The systematic review 
also underlined the difficulty in measuring the severity of prescription errors (174).
Most of the prescription errors in this present study were of the type ‘lack of PRN
regime’ where the physician had prescribed PRN medications without specifying a
maximum dosage per day. 
Methodological considerations 
The majority of studies on errors in the medication process have, so far, primarily 
been conducted in somatic hospital settings with only a few studies including a 
psychiatric population. This present study provides an important contribution to the 
current knowledge about errors in the medication process in psychiatric hospitals 
due to methodological choices. On the one hand, the study sample was small - only 
67 patients were included - which is thus a potential weakness of the study. On the 
other hand, using ‘opportunity for error’ as a denominator provides the strength of a 
larger sample. The strength of the study is the choice of method for detecting errors 
in each stage of the medication process. For each stage, the most sensitive method 
was applied (51,52,175) and the potential bias in observational studies was 
identified and quantified through the unannounced control visit. However, this was 
not completely successful, as the majority of errors was associated with one nurse 
assistant, leading to a diminished reliability when comparing with other hospitals or 
settings where the dispensing of drugs is undertaken by the pharmacy. The study 
appears to have good internal validity, but was carried out in a single university 
hospital with a limited generalizability as consequence. Nevertheless, other 
psychiatric hospitals might face similar issues with medication safety and –in 
comparison with somatic hospitals – may be equally challenged in improving the
quality of the medication process.
Study I included prescription errors related to the communicating of the 
prescription, but not the decision-making part of prescribing and in the process of 
assessing prescription errors related to the communicating of prescriptions, the 
research group identified a number of potentially inappropriate patterns of 
prescribing which led to the design of Study II.
6.2.2. STUDY II (CHARACTERISTICS OF PIPS)
This study reported that 59% of all patients admitted to a bed unit had one or more 
PIPs which is supported by a systematic review reporting a prevalence of PIPs for 
the elderly, ranging from 21.4%-79.0%. Their finding represents a wide range and 
one may speculate whether this represents local patterns of prescribing as the 
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criteria used in the detection of PIPs are the same. The finding of the use of 
combination therapy with antipsychotics or antipsychotic polypharmacy (the use of 
one or more antipsychotics) as the most frequent PIP is hardly surprising as the 
practice of antipsychotic polypharmacy has been extensively investigated,
cautioned against except for certain specific circumstances, and found to be 
frequent worldwide (176). Another finding in this present study was the use of 
combination therapy with antipsychotics and antidepressants which several times 
was assessed as potentially harmful. Studies have investigated major depressive 
disorder (MDD) and there is partial evidence for the augmentation of treatment with 
second-generation antipsychotics to antidepressants, however this is also 
accompanied by a higher risk of adverse events (177,178). Older studies 
demonstrated polypharmacy and somatic illness as predictive factors of PIP 
(179,180). This present study confirmed the same to be the case in a psychiatric 
population and this is emphasised by a study of psychiatric comorbidity on 30-day 
all-cause readmissions after heart failure, acute myocardial infarction and 
pneumonia (181). The latter study found a significantly higher readmission rate for 
patients with psychiatric comorbidity compared to patients without comorbidity. In 
the present study, patients receiving five or more medications had an almost two 
and a half times higher risk of potentially serious or potentially fatal PIPs than 
patients receiving less than five prescriptions. Additionally, having one or more 
somatic diagnoses yielded an almost two times higher risk of potentially serious or 
potentially fatal PIPs than patients with no somatic diagnoses. Age was not a 
statistically significant predictor of PIP but this might be due to psychotic disorders 
being the most prevalent mental disorder in young patients and the consequential 
treatment with antipsychotics. 
When comparing the findings from this study and those of a literature review 
regarding what are considered to be high-risk drugs, there were several drugs in 
common (182). Some examples are methotrexate, NSAID, opioids, acetylic 
salicylic acid, other anticoagulants, beta-blockers, antibiotics, sulphonylureas, 
antipsychotics, and antidepressants. Consequently, what are considered high-risk 
drugs in somatic hospitals are also prevalent in psychiatry and should receive equal 
attention when prescribed for patients with psychiatric disorders.
Methodological considerations
There are several strengths to this study. To the author’s knowledge, this is the first 
study to apply medication reviews carried out by clinical pharmacologists in newly 
admitted psychiatric patients. The clinical pharmacologists had extensive 
pharmacological expertise as well as clinical knowledge of psychiatric patients and 
applied this in the detection of PIPs and the assessment of potential clinical 
consequences. The aim was a detailed picture of the appropriateness of prescribing 
for psychiatric patients at the time of admission, and where other studies have 
applied explicit criteria, this study applied an implicit approach. The explicit criteria 
is tantalising from a researchers point of view but not satisfactory, as not all 
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possible PIPs can be listed and will not necessarily apply to all individuals (90,183).
The advantage of the implicit approach is the holistic viewpoint, in which all the 
patients medications are included along with the patient’s preferences, best 
available evidence and the individual traits of knowledge and experience of the 
clinician (90,103). However, the implicit approach where only one clinical 
pharmacologist carried out the medication review and assessed PIPs for potential 
clinical consequences might introduce a less reliable result. Assessment by 
consensus has been used in one of two forms: a) agreement among peers without 
preset criteria; and b) a process such as the Delphi technique until consensus was 
reached (183). This is not without problems either, as experts can agree and yet be 
wrong (184).
In Study II, it was concluded that there was a need to improve physicians’ 
knowledge of pharmacology as well as nurses’ knowledge of medication safety 
issues. Study III emerged in recognition of nurses’ central role in handling 
medication.
6.2.3. STUDY III (NURSES AND PIP IDENTIFICATION)
In this study, medication reviews were also used to detect PIPs following the same 
procedure as in Study II. However, this present study found a higher prevalence of 
PIPs (66% of patients) than the prevalence of PIPs identified in Study II (59% of
patients). In a recent study, in older patients admitted to psychiatric hospital, 
researchers found, that 47% and 79% of all patients had potentially inappropriate 
medications (106) using Beers Criteria 2012 (185) and STOPP (186), respectively. 
These findings support this present study where 66% of the patients had one or 
more PIPs.
The nurses found 38/224 (17%) of all PIPs identified by the SCPPs in the same 
sample. This is not a result directly comparable to other studies, as the finding is 
one of the first attempts to quantify to what extent and within which categories 
nurses identify PIPs in psychiatric patients. Both nurses and SCPPs identified the 
majority of PIPs in the category ‘interaction between drugs’ where the nurses 
identified 24/64 (38%) of PIPs also identified by the SCPPs. In a study from 
Sweden, where nurses identified drug-related problems (DRPs), it was found that 
22% of the identified DRPs were potential drug interactions (23) as opposed to the 
24/64 (38%) identified in this present study. The Swedish study based the data 
collection on a tool screening for symptoms in the patient, whereas this present
study based the data collection on the appropriateness of prescriptions. Thus the 
prevalence in the Swedish study might be lower as the explicit criteria of the 
screening tool is only sensitive to patients already presenting with ADRs and does 
not apply to all prescriptions for all patients. 
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Nurses and SCPPs identify and observe PIPs based on two different foundations. 
Nurses use guidelines, knowledge about the patient, whatever pharmacological 
training they have received, occasional self-studies, and will ask colleagues for 
advice (153,187) whereas the SCPPs in this study strictly applied evidence based 
guidelines and clinical pharmacological reasoning.
Physicians’ acceptance rate of changing medications, according to pharmacists’ 
suggestions, for instance, has been found to be moderate (188,189). Physicians may 
be more likely to accept advice or suggestions on medication from another 
physician and are, as mentioned before, less inclined to do so if the medication 
counselling is given by a pharmacist (190). In a survey of physicians’ perceptions 
of medication counselling, 30% of the physicians found it of major importance that
the person providing medication counselling was part of the team, but only 18% 
found it to be of major importance that the person providing the medication 
counselling was a pharmacist (190). Data does not tell whether a person who is
‘part of the team’ could be a nurse, seen through the eyes of the physician. 
Nevertheless, physicians in the present study changed or altered prescriptions for 
47/137 (34%) of the PIPs identified by nurses. However, only 8/47 (17%) of 
prescriptions altered by the physicians were also prescriptions identified by the 
SCPPs. 
All errors are important in medication research, as even insignificant errors indicate 
flaws in the medication process which again might result in harm given other 
circumstances (27). The nurses identified potentially serious, and even potentially 
fatal PIPs, but also PIPs of minor clinical importance indicating that nurses’ 
achievements in medication-related activities, such as evaluating prescriptions, 
ensuring patient adherence to medication, and observing effects and side effects of 
medication is an overlooked activity in need of future examination of their potential 
in this area.
Methodological considerations
There were several strengths in the study. The first of these was the pharmacology 
course where the nurses were trained to observe and identify PIPs in a consistent 
and systematic way. Second was the use of the SCPPs’ medication review as the 
gold standard against which the nurses’ observations were validated and third was 
the documentation of physicians’ alterations to prescriptions in response to nurses 
observations of PIPs. Finally, the before-and-after design with a control group 
provided a baseline for observing any increase or decline in the prevalence of PIPs 
indicating if other factors influencing the prevalence of PIPs. The DID approach 
provided an estimate of the potential reduction in PIPs between the control and the 
intervention group controlled for permanent differences between the control and the 
intervention group (191). Bias from comparisons over time, because of trends, was 
also controlled (191). There were also limitations to the study. Prescribing patterns 
in the study only represented one study site, and thus generalisations must be made 
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with caution. The exactness with which one can measure PIPs is uncertain and will 
depend on the adopted approach (90). Randomisation and blinding were not 
feasible. Randomisation on the individual level was unsuitable due to the risk of 
educational bias between nurses on the bed units. Blinding was unsuitable due to 
the nature of the intervention. Additionally, there were no assessments of intra-rater
reliability for the SCPPs; however, the interrater reliability between nurses and 
SCPPs for identifying a patient as having a PIP was assessed. Finally, the choice of 
SCPPs’ medication reviews proved somewhat problematic as it produced the 
question of relevance and characteristics of the sizeable proportion of PIPs 
identified by the nurses and responded to by the physicians, which were, however, 
not suggested as PIPs by the SCPPs.
The nurses participating in Study III, also participated in the focus group interviews 
on which Study VI is based. The focus group interviews were carried out before the 
intervention period in Study III and have helped shed some light on some of the
subsequent results in Study III.
6.2.4. STUDY IV (NURSE-PHYSICIAN COLLABORATION)
This study about nurses’ perceptions of collaborating with physicians regarding 
medication optimisation for psychiatric patients, may explain aspects of the other 
studies on which this thesis rests. During the focus group interviews, nurses 
consistently talked about physicians who were initiators in NPC as ‘good 
collaborators’. Surprisingly, they did not bring up nurses as facilitators for NPC. 
There is evidence indicating that positive NPC relationships bring about several 
beneficial outcomes for both patients, nurses, and physicians (121,126,192,193).
The potential consequences of NPC relationships for patient outcomes and job 
satisfaction are scarcely investigated in psychiatry. Some nurses in this present 
study spoke of ‘access to the physician’ as something difficult to obtain yet a 
prerequisite for discussing and passing on valuable information about their patients. 
Physicians were seen by the nurses as an opportunity for increasing knowledge 
about medication and treatments to improve their nursing competencies. Kramer 
and Schmalenberg have performed many studies investigating nurse-physician 
relationships, and an excerpt of their work is the suggestion of five types of nurse-
physician relationships. The five types of relationships are ‘the collegial’ (described 
as equal trust, power, and respect), ‘the collaborative’ (described as mutual trust, 
power, and respect), ‘the student/teacher’ (where either nurse or physician can be 
teacher and the other willing to listen and learn), ‘the friendly stranger’ (described 
by the formal exchange of information and a neutral tone), and ‘the 
hostile/adversarial’ (described by anger, verbal abuse, threats, or resignation) 
(194). Nurses in the present study primarily described collaboration in terms best 
characterised by ‘the student/teacher relationship’ and ‘the friendly stranger 
relationship’. One may speculate that the results from Study III where physicians 
responded to a modest proportion of PIPs identified by the nurses, of which an even 
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smaller proportion were identical to the SCPPs findings, is a manifestation of the 
type of collaboration taking place. The picture is not clear, as the physicians have 
displayed a willingness to alter prescriptions based on nurses observations, however 
only a small proportion of prescriptions altered were also identified as PIPs by the 
SCPPs.
A ‘magnetic’ hospital is a hospital where nurses are consistently attracted, retained 
and deliver high-quality care. The environment in a hospital is said to be magnetic 
when attributes considered important to job satisfaction and productivity of quality 
care by staff nurses, are also present (195). Though physicians tend to view 
collaboration less important than nurses (123,196), nurses’ job satisfaction and 
perceptions of achieved quality in care for patients is closely linked to positive NPC 
relationships (193,194). The nurses in this present study also expressed the 
viewpoint that positive NPC on medication optimisation was rewarding in terms of 
achieved quality and job satisfaction. Additionally, it also became clear that the 
nurses’ experience of ‘a magnetic environment’ was linked to the organisation of 
the collaboration between physicians and nurses, e.g. ward rounds. 
The focus group interviews gave rise to some interesting reflections by nurses who 
had somatic experience and were now employed in the psychiatric bed units. The 
findings indicated that nurses with somatic experience perceived some differences 
in NPC in psychiatric hospitals compared to somatic hospital settings. These nurses 
with somatic experience described the NPC in less favourable terms in psychiatry. 
They would use wording consistent with collegial and collaborative nurse-physician 
relationships about their work in somatic settings and while describing their current 
situation with wording consistent with the friendly stranger relationship or even, in 
a few cases, a hostile/adversarial nurse-physician relationship. Whether this 
expresses that nurses experience more satisfactory NPC regarding medication 
optimisation in somatic hospital settings than in psychiatric hospital settings 
remains to be studied. It must be considered that the nurses, with the wisdom of 
hindsight, recalls the work conditions in somatic hospitals as being better than what 
they actually were.
The nurses considered the ward rounds to be the primary point of contact with 
physicians, and findings in the present study indicate that the setup of ward rounds 
plays a vital role in how nurses view their opportunities for collaborating with 
physicians regarding medication optimisation.
There were two primary perceptions of the nurses’ self-perceived competencies and 
responsibilities in terms of medication optimisation. The first perspective was 
nurses being competent and central in communicating with patients about 
medication. The other perspective was more unforthcoming where nurses 
questioned the extent and relevance of their knowledge to be good collaborative 
partners to physicians. The most cautious nurses questioned whether nurses have 
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any role in medication optimisation and suggested that responsibility for 
appropriate medication rests solely with the physician. The nurses’ reflections also 
touched on the experience of not having enough knowledge. Sometimes the nurses 
would handle, and administer medications of which they knew nothing, except for 
what could be looked up online or what could be found in the patient’s information. 
This finding is supported by Happel et al., who described that nurses report 
knowledge sources such as the Internet, using information pamphlets meant for 
patients, consulting pharmacists and using drug representatives as a source of 
education (153). Another study also found that nurses expresses limited knowledge
about pharmacology while seeing knowledge about pharmacology as essential for 
clinical practice (197). However, a more recent cross-sectional, Swedish study 
demonstrates that nurses self-perceived competencies and pharmacovigilant 
activities are significantly higher after receiving university-based pharmacology 
courses than if they had not participated in such courses (198).
Methodological considerations
The purpose of the study’s design was to describe themes emerging from a specific 
site (199), not to ensure or evaluate whether the study’s results were representative 
for nurses employed in psychiatric bed units. Due to the nature of focus group 
interviews, the study had some inherent weaknesses. Firstly, focus groups will often 
consist of participants who are not familiar with one another to prevent participants 
being inhibited or subservient due to characteristics with-in the group (169,199).
This present study included, in each focus group, nurses who knew each other from 
their current workplace and nurses who were not familiar with each other. This 
choice was made because the present study links to the context in which Study III 
was carried out. The combination of everyday colleagues and colleagues from 
another bed unit opened up the possibility of addressing issues that might not be 
touched upon on a day-to-day basis in the individual bed units but also to 
investigate differences between two seemingly uniform bed units. There is always 
the risk of the group dynamics influencing the individual to support the viewpoint 
most acceptable to the group (170). However, all nurses spoke at one or more points 
during the interviews. The phrasing of questions and conducting of data analysis 
have obvious potentials, for influencing outcomes. Attempts to avoid this included 
an independent researcher, who was not involved in the study in any way, checking 
correctness of transcribing, and consensual discussions between the researchers 
throughout the process of developing relevant themes. Data saturation might not 
have been met, due to the evident limitations in having only two focus groups. This 
excludes the necessary iterative process (200). Conversely, identical themes 






The purpose of this thesis was to investigate the extent and nature of errors in the 
medication process, PIPs, and nurses’ potential role in improving the quality of 
prescribing for psychiatric patients. 
The objective in Study I was to evaluate the prevalence, types, and potential clinical 
consequences of errors in the medication process in psychiatric wards. The study 
demonstrated errors as a real and comprehensive problem in psychiatric hospitals 
with most errors occurring in the administration stage. Additionally, establishing a 
patient’s identity before administration of medication was the most frequent type of 
error. Using a definition that discriminates errors from medication errors by the 
potential for harm to the patient revealed that only a small proportion of errors in 
the medication process appears to be potentially fatal. However, the majority of 
errors in the administration stage were assessed as potentially serious. 
The objective in Study II was to evaluate the prevalence, types, and predictors of 
PIPs as well as the severity of potential clinical consequences. The study revealed 
PIPs to be frequent with drug interactions as both the most frequent PIP but also the 
most important category in terms of potential harm or fatality to patients. It was 
also demonstrated that polypharmacy and the presence of somatic comorbidity were 
factors predictive of PIPs.
The objective in Study III was to examine the characteristics, magnitude, and 
potential effect of pharmacologically trained nurses’ systematic review of 
medication records on the appropriateness of prescribing for newly admitted 
psychiatric patients. The study did not show any statistically significant potential 
improvement in PIPs, either in the mean number of PIPs per patient or the number 
identified PIPs also identified by SCPPs and assessed by SCPPs to be potentially 
harmful to patients. Physicians responded to some of the nurse-identified PIPs, but 
assessed the majority of nurse-identified PIPs as not clinically relevant.
The objective in Study IV was to explore how nurses perceive collaborating with 
physicians on medication optimisation for psychiatric patients. The study addressed 
nurses’ views and perceptions of medication optimisation as a result of NPC. The 
limited success in Study III might be partially explained by the findings in Study 
IV. The nurses primarily described relationships characterised by a ‘student-teacher 
relationship’ and a ‘friendly stranger relationships’. Study IV raises expectations 
that skilled and confident nurses can provide physicians with precise and adequate 
information to share responsibility for medication optimisation and can provide 
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patients with high-quality information and support their adherence to appropriate 
medications.
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Much research and effort has been spent on definitions and classification of 
medication errors, including the definitions used in this thesis (26,29–31,201).
Many researchers have also tried to establish frequencies of medication errors using 
a variety of methods (17,40,77) and the special challenges facing psychiatry in this 
regard have also been touched upon (16,203). Some examples are TDM and off-
label prescribing. However, the reality is most likely that an exact frequency of 
medication errors will remain unknown (27), as both method of detection and 
terminology can affect outcome (27,31). Yet, it is crucial to continue monitoring 
errors and medication errors to determine where improvement interventions are 
needed.
As the exact frequency of medication errors will remain unknown, so will the exact 
frequency of PIPs remain unknown, as ‘appropriateness is in the eye of the 
reviewer’ and formed by evidence and the individual knowledge and experience of 
the clinician (89). However, the presence of PIPs is indisputable and in addition, an 
issue that needs to be addressed sensitively and rationally to prevent patients from 
suffering unnecessary doubt or anxiety about their medication and to keep the 
debate nuanced and based on evidence.
Several times during the research for this thesis, physicians have asked: ‘but did you 
identify any patients harmed by PIPs?’. On the one hand, there were no patients 
identified who had suffered any harm at the time, which is hardly surprising as the 
study design is cross-sectional and only seeks to measure the presence of PIPs – not 
its actual consequences which requires a prospective design. On the other hand, the 
question of whether PIPs actually harm patients is valid – yet, unanswered. With 
that established, it is necessary to mention that during the data collection period, the 
research group was acquainted with a handful of incidences suspected to be 
medication-related. In the future, large-scale studies that prospectively investigate 
the consequences of PIPs should be considered.
The present thesis also addressed nurses’ role in medication safety in psychiatry. 
The findings in Study III indicate that systematic efforts to improve nurses’ clinical 
reasoning about the safe use of medications and their observations of effects and 
side effects provides part of the foundation on which balanced prescribing rests. 
The potential for improvement has been quantified. However, what constitutes a 
clinically relevant PIP to a physician versus an SCPP, remains to be investigated. If 
nurses are to make a positive difference in improving the quality of prescribing for 
psychiatric patients, they can only do so in collaboration with physicians.
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The results from Study IV indicate that the different types of nurse-physician 
relationships described in the literature (193,204) also exist in psychiatric hospitals. 
The results also indicate how organisational structures, for example ward rounds, 
have an impact on the quality of these nurse-physician relationships. Additionally, 
prospects are that nurses can improve their skills on the clinical observation gap 
between physician and patient by bonding nursing and medical knowledge in terms 
of NPC on medication optimisation, however, this remains to be examined further 
in the future.
Nurses are an already existing resource which, to a degree and in collaboration with 
physicians, offers hope for improvement. However, realising the potential for 
nurses to improve medication quality and safety in psychiatry, requires leadership 
and an organisational will to give room to NPC. NPC implies that interprofessional 
committees include both nurses, physicians, and other relevant professions, and 
regular and interprofessional reviewing of patients. Nurses’ work, including rounds 
on the bed units, must be planned with the optimisation of NPC in mind, including 
regular pharmacology and medication safety education for the nurses. Decision-
makers must realise that the abovementioned potential benefits cannot be realised 
without the will to make organisational changes.
Finally, the physicians’ perspective on NPC about medication optimisation was not 
investigated in this thesis. Shekelle et al. point to teamwork, leadership, and patient 
safety culture as some of the contextual factors impacting on the success with 
which a patient safety intervention can be implemented and sustained (159).
Therefore future studies that focus on the physicians’ views and perceptions of NPC 
in terms of medication optimization, but also medication safety in general are 
needed.
The finishing remark is given to an American nurse, who as early as 1939, in The 
American Journal of Nursing (205) wrote:
‘Nurses are in a peculiar and often difficult situation in 
carrying out the orders of physicians. Friction may arise 
where it could be avoided if both nurses and doctors would 
remember that the only thing which really matters is the 
welfare of the patient, not that one group gives, and the other 
carries out the orders’. 
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Study I. (Errors in the medication process). 
aThese error types are all included in the error type ‘Ambiguous drug prescription’.
Adapted from Lisby M, Nielsen LP, Brock B, et al. How should medication errors be defined? 
Development and test of a definition. Scand J Public Health. 2012, by permission of the Nordic Society 




Study II and III.
Reproduced from ‘Potentially inappropriate prescriptions in patients admitted to a psychiatric hospital’, 
Nordic Journal of Psychiatry, copyright © Nordic Psychiatry Association, reprinted by permission of 













*The highlighted areas represent errors with the potential to harm patients. 
Reproduced from Lisby M, Nielsen LP, Mainz J. Errors in the medication process: frequency, type, and 
potential clinical consequences. 
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Purpose: To investigate the frequency, type, and potential severity of errors in several stages 
of the medication process in an inpatient psychiatric setting.
Methods: A cross-sectional study using three methods for detecting errors: (1) direct 
observation; (2) unannounced control visits in the wards collecting dispensed drugs; and 
(3) chart reviews. All errors, except errors in discharge summaries, were assessed for potential 
consequences by two clinical pharmacologists.
Setting: Three psychiatric wards with adult patients at Aalborg University Hospital, Denmark, 
from January 2010–April 2010.
The observational unit: The individual handling of medication (prescribing, dispensing, 
and administering).
Results: In total, 189 errors were detected in 1,082 opportunities for error (17%) of which 84/998 
(8%) were assessed as potentially harmful. The frequency of errors was: prescribing, 10/189 (5%); 
dispensing, 18/189 (10%); administration, 142/189 (75%); and discharge summaries, 19/189 
(10%). The most common errors were omission of pro re nata dosing regime in computerized 
physician order entry, omission of dose, lack of identity control, and omission of drug.
Conclusion: Errors throughout the medication process are common in psychiatric wards to an 
extent which resembles error rates in somatic care. Despite a substantial proportion of errors with 
potential to harm patients, very few errors were considered potentially fatal. Medical staff needs 
greater awareness of medication safety and guidelines related to the medication process. Many 
errors in this study might potentially be prevented by nursing staff when handling medication 
and observing patients for effect and side effects of medication. The nurses’ role in psychiatric 
medication safety should be further explored as nurses appear to be in the unique position to 
intercept errors before they reach the patient.
Keywords: medication safety, mental health disorders, medication errors, psychiatry
Introduction
Adverse drug events (ADEs) and medication errors (MEs) are recognized as an impor-
tant quality and patient safety problem in modern hospital settings, causing harm as 
well as avoidable morbidity and mortality.1–5
There is limited evidence about these issues in psychiatric settings. Only a few 
studies on ADEs and MEs in psychiatric hospital settings exist. Four of these studies 
addressed prescribing errors and two studies addressed administration errors.6–11
Results from three of the studies investigating prescribing errors displayed 
a rate of decision-making errors which ranged from 12.5%–23.7% and a rate of 
documentation (clerical) errors, which ranged from 76.3%–84.5%.7–9 The fourth 
study, aimed at describing errors in the prescribing phase, was based on reports 
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about pharmacists’ interventions.6 In the two studies which 
focused on administration errors, one study was based on 
self-reporting by nurses and did not report any rate of error. 
The other study was an observational study of administration 
errors in elderly psychiatric inpatients where administra-
tion errors were detected in 25.9% of all opportunities for 
error.10,11 Some studies have investigated several stages in the 
medication process, but these studies were primarily based on 
data collected from self-reporting of medication errors and 
chart reviews.12–15 These studies measured their outcomes 
using different methods and denominators which makes it dif-
ficult to conduct comparisons. However, it is recognized that 
direct observation is the most valid method when collecting 
data in the dispensing stage and the administration stage.16 
It is highly important to apply reliable methods when inves-
tigating frequency and character of errors in the medication 
process to produce valid and precise information.16,17
To our knowledge, there are no studies in psychiatric 
hospital settings which focus on errors in more stages of 
the medication process, including discharge summaries, by 
applying the most sensitive methods of detection. A precise 
estimate of frequency, type, and potential severity of errors 
is needed to choose relevant interventions to reduce errors 
in the medication process. Therefore, the objective of this 
study was to investigate the frequency, type, and potential 
severity of errors in several stages of the medication process 
in an inpatient psychiatric setting.
Materials and methods
The medication process can be divided into prescribing, 
dispensing, administering, and monitoring.18
Furthermore, the prescription stage of the medication 
process can be divided into a decision-making process and 
a clerical process. The decision-making process concerns the 
physician’s choice of drug, dose, and form of administration.18 
The stage of monitoring the patient for effects and side effects 
was not included in the study.
An error was defined as “a planned action which failed 
to achieve the desired consequences.”19 This means that all 
deviations from guidelines were considered errors; subse-
quently, two clinical pharmacologists evaluated all errors for 
potential severity, thereby separating harmless errors from 
errors with the potential to harm patients.
Describing proportions of errors requires a defined 
denominator.20
“Opportunities for error”, defined as opportunities for 
active errors (omissions, mistakes, and/or conscious or 
 unconscious rule violations), was the denominator used to cal-
culate the proportion of errors in this study. The denominator 
is established by multiplying the number of handled medica-
tions with the number of requirements in the guidelines to be 
followed. The proportion of errors was the sum of actual errors 
divided by the total number of opportunities for errors.
Design
The study was designed as a descriptive, cross-sectional 
study of errors in the medication process and potential harm. 
Data was collected using three methods: direct observation; 
unannounced visits to the wards to collect dispensed drugs 
for identification; and chart review. The study population 
included in-hospital patients aged 18 or above (n  67), 
nurses and nurses’ assistants dispensing and administering 
drugs, and physicians prescribing drugs, but the observational 
unit was the individual handling of medication (prescribing, 
dispensing, and administering). It is common in Denmark 
that each ward has its own stock ward system where nurses 
 dispense drugs. The term “dispensing” refers to nurses iden-
tifying the drugs prescribed and dispensing it to medication 
cups. Subsequently, the nurses will administer the medica-
tions to patients. The hospital pharmacy staff undertakes 
monitoring the use, needs, and reordering of drugs as well 
as giving advice for the individual wards. In this study, 
regular and pro re nata (PRN) prescriptions were included, 
apart from discharge summaries in which PRN prescriptions 
were excluded. The choice of excluding PRN prescriptions 
in discharge summaries was made because physicians often 
forget or are not aware that a PRN drug deliberately not 
prescribed in the discharge summary must be discontinued 
in the computerized physician order entry (CPOE). Includ-
ing this as an error type would give a distorted impression 
of the prevalence of errors in discharge summaries. PRN 
prescriptions are prescriptions not scheduled to be adminis-
tered at predetermined times of the day but to be used “when 
needed.” Errors in discharge summaries were not evaluated 
for potential severity, due to practical reasons. Included 
drug forms were tablets, capsules, mixture, suppositories, 
and injections.
Study site
This study was conducted in three psychiatric wards at 
Aalborg University Hospital, Denmark, from January 2010 
to April 2010. Physicians were responsible for prescribing 
drugs and nurses or nurses’ assistants were responsible for 
dispensing and administering medication. There was no 
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administration of drugs scheduled in the night shift. Drug 
prescriptions were documented in a CPOE system.
Methods for collecting data
All comparisons of observations to the CPOE were conducted 
by one of the authors (ALS).
Observational method
Data were collected on the wards using direct observation. 
The observer spent two day shifts (8 hours) and one evening 
shift (8 hours) on each ward, observing the nurse or nurs-
ing assistant responsible for dispensing and administering 
drugs. The observations covered six rounds of dispensing 
and administering drugs in each of the three wards. The 
caregiver responsible for the entire medication administra-
tion in the ward was aware of the study purpose but had 
no knowledge about which actions were observed and 
registered. The observations of dispensed and administered 
drugs were registered on a structured paper form and subse-
quently compared with prescriptions in the CPOE. Due to 
the tradition and rules of observing the patients’ consump-
tion of medication in psychiatric nursing, it was possible 
to register all administered medication. Any discrepancies 
between the observed and the prescribed medication in the 
CPOE were classified as errors, according to the criteria 
outlined in Table S1.
Unannounced visit to the ward
The unannounced visit to the ward was conducted approxi-
mately 3 weeks after the observational study. The dispensed 
medication was collected from the medication storage room 
before administration. The medicine collected from the 
medication storage room was subsequently compared to 
the CPOE. Any discrepancies between the identified drugs 
and the prescriptions in the CPOE were classified as errors, 
according to the criteria outlined in Table S1.
Chart review
The CPOE and discharge summaries were retrospectively 
screened for errors. It was assessed whether drug pre-
scriptions were in accordance with the criteria outlined in 
Table S1. If a patient was sampled more than once, only new 
or altered prescriptions were screened for errors. Discharge 
summaries were also screened to identify errors, ie, dis-
crepancies between eligible prescriptions in the CPOE and 
the discharge summaries, according to the criteria outlined 
in Table S1.
Potential clinical consequences
All registered errors in the observational study, screening of 
the CPOE (errors in discharge summaries excluded), and the 
unannounced visits to the wards to collect dispensed drugs 
were assessed for potential clinical consequences. The assess-
ment was conducted independently by two senior clinical 
pharmacologists using a four-scale system: potentially fatal; 
potentially serious; potentially significant; and potentially 
nonsignificant.5 The four-scale classification system can be 
found in Table S2.
Statistics
All data were analyzed using Stata/IC 10.0 (StataCorp, 
College Station, TX, USA). Frequencies were described as 
percentages. The kappa test was used to evaluate the inter-
rater variation in the clinical pharmacologists’ assessment 
of potential clinical consequences where appropriate. The 
statistical significance level was set at 0.05.
Ethics
Approval of the study was obtained from the Danish Data 
Protection Agency. The investigator was ethically obliged to 
intervene in the case of observing an error. If the investigator 
had to intervene, it was registered as an error.
Results
Patients
The study included 67 eligible patients (24 men [36%] and 
43 women [64%]) with a mean age of 46 years (20–79 years). 
The most common reason for admission was schizophrenia 
and other psychotic disorders (22/67;33%), followed by 
bipolar disorders (11/67;16%).
Frequency of errors
A total of 189 errors were detected in 1,082 (17%) oppor-
tunities for errors. The frequency of errors in the different 
stages of the medication process is shown in Table 1. The 
majority of errors were detected in the administration stage 
with errors in 142/340 (42%) opportunities for error. This 
was followed by discharge summaries with errors in 19/84 
(23%) opportunities for error. Nine (47%) errors in discharge 
summaries were due to eligible prescriptions in the CPOE, 
which were not prescribed in the discharge summary.
The intention behind investigating the dispensing stage 
using two methods was to examine the validity of the results 
obtained in the observational study. There were errors in 
9/324 (3%) opportunities for error of the dispensed drugs in 
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the observational study and in (9/67) 13% of the dispensed 
drugs in the unannounced control visit of which the majority 
was associated with one nurse assistant. Fewest errors were 
detected in the prescribing stage.
Frequency of error types
The identified errors were distributed by error types which are 
shown in Table 2. The most frequent error types were lack of 
identity control (135/142; 95%) and concordance with drug 
prescription (10/142; 7%). The error type lack of identity 
control occurs when the patients’ identity is not established 
before administering drugs. The clinical guideline states that 
the person administering the drugs must identify the patient 
by having the patient say his full name and Social Security 
number, or by using the obligatory wristband to identify the 
patient. The error type concordance with drug prescription 
occurs if already-dispensed drugs are delegated to another 
staff member; this person must compare the drugs to be 
administered with the prescriptions in the CPOE. Error types 
in the administration stage could be mutually dependent. This 
occurred with the following error types: “lack of identity 
control;” “wrong time;” and “lack of correct labeling.” The 
dependency arises because each of the aforementioned error 
types affects all doses which were delivered to the patient 
in that particular incidence. Analysis of these error types 
showed that “lack of identity control” occurred in 49 of 137 
(36%) deliveries. “Wrong time” occurred in four of 137 (3%) 
deliveries. Finally, “Lack of correct labeling” occurred in 
three of 137 (3%) deliveries.
Assessment of potential clinical 
consequences
The assessment of the potential clinical consequences was 
carried out in a worse-case scenario, meaning that whenever 
the clinical pharmacologists disagreed on the severity of an 
error, the most severe assessment was included in the analy-
sis. Results from the assessment are displayed in Table 3; 
definitions are outlined in Table S2. The inter-rater agreement 
(measured by the test statistic kappa) for errors in prescribing, 
dispensing, and  administration varied from good to perfect 
(0.54; 0.75; 0.82; and 1.0, respectively).21
The pharmacologists assessed 84/998 (8%) errors as 
potentially serious or potentially fatal. The number of oppor-
tunities for error in this part of the study was reduced to 998 
because assessment of potential clinical consequences did not 
include errors in discharge summaries. The four potentially 
fatal errors were related to the error types: “omission of PRN 
dosing regime” (n  2) and “lack of identity control” (n  2). 
There were errors in 142/340 (42%) of all opportunities 
for errors in the administration stage, and it was assessed 
that 75/142 (53%) of these errors had the potential to harm 
patients.
Drug categories and errors
Errors with the potential to harm patients were most often 
associated with drugs related to the patients’ psychiatric 
condition (Table 4). The drug category most often associ-
ated with these errors was psycholeptics. The type of drug 
most often involved in potential harmful errors was atypi-
cal antipsychotics, followed by anxiolytic-sedative drugs 
and mood stabilizers. The errors assessed to be potentially 
fatal were related to prescribing and administration of 
medication and were associated with analgesics (opioids) 
(n  2) and psycholeptics (atypical antipsychotics) (n  2). 
Nonpsychiatric drugs associated with potential harmful 
errors constituted 7/77 (9%). The majority of these errors 
were anti-inflammatory and antirheumatic drugs, including 
nonsteroidal anti-inflammatory drugs (NSAIDs).
Discussion
There were errors in almost one-fifth of all handlings of 
medication of which the vast majority occurred in the admin-
istration stage. The main type of errors was lack of identity 
control. The prevalence of potentially harmful errors was 8%, 
of which 0.3% errors were considered potentially fatal. The 
potentially fatal errors involved drugs from the categories 
of analgesics and psycholeptics. A few other studies in psy-
chiatry have examined administration errors and identified 
Table 1 Frequency of errors in the different stages of the medication process
Prescribing,  
CPOE n/Ntotal (%)
Dispensing, observational  
study n/Ntotal (%)






10/267 (4) 9/324 (3) 9/67 (13) 142/340 (42) 19/84 (23)
Notes: Ntotal, the total number of opportunities of errors in each stage (prescription and doses); n, the total number of detected errors in each stage of the medication 
process. The difference in number of dispensed medications and number of administered medications in the observational study was due to incidents where staff had 
administered medicine without the investigators’ presence.
Abbreviation: CPOE, computerized physician order entry.
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Table 2 Frequency of error types in the different stages of the medication process
Stage in medication 
process
Total number of doses or prescriptions  
affected with at least one error in each  
stage of the medication process (N)
aTotal number of error  
types in each stage (n/N)
Prescribing, CPOE N  10
 Drug name 0
 bDrug prescription 2/10
  cOmission of PRN dosing in CPOE 8/10
Dispensing, observational study N  9
 Drug prescription 0
 Omission of dose 3/9
 Wrong dose 1/9
 Unordered dose 0
 Contamination 1/9
 Lack of correct labeling 4/9
Dispensing, unannounced control visit N  9
 Drug prescription 0
 Omission of dose 6/9
 Wrong dose 2/9
 Unordered dose 1/9
Administration N  142
 Omission of dose 0
 Wrong dose 1/142
 Unordered dose 0
 Contamination 0
 dLack of correct labeling 0
 eWrong time 8/142
 Wrong route 0
  Wrong administration technique 0
 fLack of identity control 135/142
 Wrong patient 0
  gConcordance with drug prescription 10/142
Discharge summaries N  19
 Drug name 1/19
 Drug prescription 9/19
 Omission of drug 9/19
Notes: aOne dose or prescription affected by an error could be associated with more than one error type; bdrug prescription: means one or more errors (including 
omissions) in strength per unit, route of administration, form of administration, dose, frequency of administration, signature, date, duration of treatment (only antibiotics 
was included in this study); comission of PRN dosing regime in CPOE: means one or more errors (including omissions) in strength per unit, route of administration, form 
of administration, dose, frequency of administration, signature, date, duration of treatment; dlack of correct labeling: means that all drugs administered to patients must be 
marked with the patient’s full identity; ewrong time: means the drugs were administered 60 minutes off the scheduled time; flack of identity control: means that the patient’s 
identity has not been established by having the patient state full name and Social Security number or using the obligatory wristband; gconcordance with drug prescription: 
means that when dispensed drugs are delegated to another staff member, this person must compare the drugs to be administered with the prescriptions in the CPOE.
Abbreviations: CPOE, computerized physician order entry; PRN, pro re nata.
the error types mismatching between medication and patient 
and wrong patient. One study found mismatching between 
medication and patient to occur with the second highest 
frequency; whereas, the second study found wrong patient 
to constitute 4/108 (3.7%) of all administration errors.10,14 
These results emphasize the importance of systematically 
identifying patients to secure the right medication for the 
right patient. We found that administration errors consti-
tuted 142/340 (42%) of all errors, which is in contrast to 
a USA study of several stages in the medication process, 
which demonstrated that 10% of all medication errors were 
identified in the administration stage.15 This disparity is most 
likely due to variation in error types. In an observational 
study of administration errors in elderly psychiatric patients, 
errors were identified in 369/1423 (25.9%) of opportunities 
for error. However, this result is not entirely comparable, 
because the aforementioned study did not include the error 
type lack of identity control or any of the related error types, 
such as wrong patient or mismatching between medication 
and patient.
The severity of administration errors in psychiatric 
settings has been assessed less severe when compared 
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to administration errors in somatic hospital settings.11,15 
However, this study assessed more than one-half of all 
administration errors to be potentially serious. Many hospitals 
have introduced wristbands as a means to control patients’ 
identity, including the psychiatric hospital where our study 
was carried out. In a study of how and whether nurses identify 
patients in a psychiatric hospital setting, it was found that 
the use of wristbands was erratic and influenced by a psychi-
atric nursing culture rooted in the belief that (good) nurses 
know who the patients are.22 The inconsistency in using the 
patient’s wristband for identification has also been addressed 
in somatic settings, and it has been shown in simulation tests 
that as many as 61% of nurses do not discover an unexpected 
identity error.23,24 This raises a question about how and when 
nursing culture plays a role in patient safety and whether this 
brings advantages or barriers. Nurses are involved in many 
errors, but nurses also prevent many errors from happening.25 
It needs to be considered that nurses are the professionals 
spending most time with the patients and, therefore, function 
as gatekeepers, where they can prevent errors and harm from 
reaching the patient. Nurses are coordinating several aspects 
of care to patients, including the care delivered by other 
health care professionals, and this is a major contribution 
to patient safety.26
Errors in discharge summaries constituted 10% (19/189) 
of all errors detected in the study. It is not possible to com-
pare these results directly to other studies due to definitions 
and categorizations; however, earlier studies of errors in 
discharge summaries in general hospital settings have found 
discrepancies in 2%–76% of the prescribed drugs.5,27,28
It has been asserted that surgery and psychiatry are 
associated with the highest rate of dispensing errors and, 
therefore, it appears reasonable to consider psychiatry a 
high-risk specialty, in regards to dispensing errors.29 We 
investigated dispensing errors using observation and unan-
nounced control visit, which showed a difference in results. 
When using observation and unannounced control visit to 
identify dispensing errors the rate of errors was 9/324 (3%) 











Prescribing, CPOE 0 4 (40) 4 (40) 2 (20)   1,0a
Dispensing, observational  
study, n (%)
0 6 (66) 3 (33) 0   0.82a
Dispensing, unannounced  
visit, n (%)
4 (44) 5 (56) 0 0   0.75a
Administration, n (%) 29 (20) 38 (27) 73 (51) 2 (1)   0.54a
Notes: aKappa test for interrater agreement; the highlighted areas represent errors with the potential to harm patients. 
Abbreviation: CPOE, computerized physician order entry.
Table 4 Categories of drugs involved in errors with potential to harm patients




 N02 Analgesics 2 0 0
 N03 Antiepileptics 0 0 9
 N05 Psycholeptics 
  – Atypical antipsychotics 
  – Typical antipsychotics 
  – Anxiolytic-sedative 
















 N06 Psychoanaleptics 







 N07 Other nervous system drug 0 1
M Musculoskeletal system
  M01 Anti-in ammatory and  
antirheumatic products
6
H Systemic hormonal preparations, excluding sex hormones and insulins
 H03 Thyroid therapy 1
Notes: Drugs are categorized according to the Anatomic Therapeutic Chemical (ATC) Classi cation System (World Health Organization Collaborating Centre for Drugs 
Statistics Methodology [WHOCC]). aIn this table, the observational and unannounced control visit in the dispensing stage have been collapsed.
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and 9/67 (13%), respectively. The difference in identified 
errors is caused by dependency in data, which arises due to 
the few nurses and nurses’ assistants involved in dispensing 
and administering medication. When pooling the results 
from the dispensing stage, the error rate was 18/391 (5%). 
This result is supported by other studies not depending on 
unit dose systems which found error rates 1% and up to 
5%.5,29,30 The most common error type in the dispensing stage 
was omitted dose, which is in accordance with a previous 
study using similar methods of error detecting but in a general 
hospital setting.5
In this present study, the clinical pharmacologists 
assessed three errors in the dispensing stage to be potentially 
serious, and no errors were assessed as potentially fatal. 
To our knowledge, there are no other studies in psychiatry 
where observed dispensing errors have been assessed for 
severity.
There were few prescription errors, but the prescription 
stage represented one-half of the potential fatal errors. Most 
of the prescribing errors were of the type “lack of PRN 
regime,” which is a type of prescription error that nurses 
are capable of intercepting. On the other hand, it also places 
nurses in a situation where they possibly make independent 
decisions as to whether a PRN medication is appropriate. 
The use of PRN medication is often solely the nurses’ deci-
sion and, perhaps, due to a lack of research into the use of 
PRN medication as an intervention in mental health care, the 
practice varies considerably.31
Strengths and weaknesses  
in the study
The majority of studies on medication errors and psy-
chopharmacotherapy have been conducted in general 
hospital settings, and very few studies include a psychiatric 
population. Thus, this study is an important contribution 
to the current knowledge, as it focuses on errors in several 
stages of the medication process by applying the most 
sensitive method to each stage in a psychiatric hospital 
setting. There were 67 patients included in the study, which 
is a relatively small sample and a potential weakness in 
the study. Observation as a method of detecting errors is 
considered a valid and well-tested method; in this study, we 
sought to substantiate the validity of observing for errors 
with the unannounced control visit.17,32 The difference in 
errors identified by observation and the unannounced con-
trol visit is solely due to the dependency in data caused by 
the few nurses and nurses’ assistants participating in the 
study. In this study, dispensing of drugs was done by nurses 
and nurses’ assistants, which might complicate comparisons 
with other hospitals and settings where hospital pharmacies 
undertake the dispensing of drugs. It appears the study has 
a good internal validity, but the study was carried out in a 
single university hospital, thus producing a limited external 
validity. However, it is evident that psychiatric university 
hospitals – in comparison with somatic hospitals – are 
equally challenged in improving the quality of the medica-
tion process.
Conclusion
Errors were found in almost one-fifth of all handlings of 
medication, and a proportion of these errors had the potential 
to harm patients. In this study, the majority of errors involved 
psycholeptics, but potential fatal errors also involved 
analgesics. Most errors were found in the administration 
stage, and studies suggest that both nursing culture as well as 
an irregular practice regarding the patient’s identity wristband 
could be a risk factor for not checking the patient’s identity. 
This could lead to the error type “wrong patient.” It might 
be beneficial to address nursing culture as well as awareness 
of existing clinical guidelines. Further studies are needed to 
investigate how and whether nurses influence medication 
safety for in-hospital psychiatric patients and how nurses can 
improve the quality of medication and medication safety for 
psychiatric patients.
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Table S1 Criteria and de nitions for error types
Stage in  
medication  
process
De nition Error types
Prescribing Unambiguous 
prescription
Omission of drug name, drug  
formulation, route, dose, dosing  
regime, date, signature, length of  
treatment time where required
Dispensing Dispensed  
medication is  
concordant with  
prescribed drug  
in electronic  
medication chart
Wrong drug, unordered dose,  
omission of dose, wrong  
dose, wrong drug formulation,  
contamination (ie, touching  
tablets without gloves), control  
of prescription (ie, controlling  
that only prescribed drugs are  
dispensed), ambiguous labeling  
of medication
Administering The right  
medication to  
the right patient  
in the right way  
and at the right 
time
Wrong: dose, administration  
technique, route, time  
( 60 minutes), unordered drug,  
unordered dose, omission of dose,  
lack of identity control, wrong  
patient (one or more  
medications administered to the 
wrong patient), contamination,  




prescriptions in  
medical record  
are identical to  
prescriptions  
in discharge  
summaries
Discrepancy in: drug name, drug  
formulation, route, dose, regime,  
omission of drug, unordered drug
Note: Adapted with permission from Lisby M, Nielsen LP, Mainz J. Errors in the 
medication process: frequency, type, and potential clinical consequences. Int J Qual 
Health Care. 2005.
Abbreviation: CPOE, computerized physician order entry.
Table S2 De nition of potential clinical consequences
Category De nition De nition of keywords
Potentially  
fatal
Errors judged to imply 
a potential clinical risk  
for causing the death  
of the patient
Fatal refers to errors that  




Errors judged to  
imply a potential  
clinical risk of injuring  
the patient
Injury includes errors that  
would require active treatment 
to restore the health of the  
patient. A potentially serious  
error would lead to either  




Errors judged to  
imply a potential  
clinical risk of being  
“inconvenient” for  
the patient – without  
causing any harm or  
injury
“Inconvenient” refers to  
unpleasant consequences  
of wrong dose/drug omission  
of dose/drug that could lead  
to pain, dizziness. It also  
refers to any monitoring of  
the patient, such as extra  




Errors judged to be  
without any potential  
clinical risk for the  
patient
Without clinical risk refers  
to errors that did not lead  
to any injury or  
inconvenience for the patient
Notes: The highlighted areas represent errors with the potential to harm patients.
Adapted with permission from Lisby M, Nielsen LP, Mainz J. Errors in the medication 
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ABSTRACT
Background Very little is known about the general appropriateness of prescribing for psychiatric
patients. Aims To identify prevalence and types of potentially inappropriate prescribing (PIP) of
psychotropic and somatic medications, to assess the severity of potential clinical consequences and to
identify possible predictive factors of PIP in a sample of adult psychiatric in-patients. Methods A
descriptive, cross-sectional design using medication reviews by clinical pharmacologists to identify PIP
during a 3-month period. The setting was in-patient units in a psychiatric department of a Danish
university hospital during a 3-month period (September 2013–November 2013). Patients medication
lists (n¼ 207) were reviewed at the time of admission and all identified PIPs were assessed for potential
consequences by clinical pharmacologists. Results There were 349 PIP identified in 1291 prescriptions.
The proportion of patients found to have at least one PIP was 123/207 (59%) and the proportions of
patients with at least one PIP assessed to be potentially serious or fatal was 69/207 (33%) and 24/207
(12%), respectively. Interactions between drugs 125/207 (36%) and too high doses of drugs 56/207
(16%) were the most frequent PIP. Predictive factors for PIP were polypharmacy (45 prescriptions) and
having one or more somatic diagnoses. Conclusion PIP is common in psychiatric patients and
potentially fatal. Particularly polypharmacy (45 prescriptions) and concomitant somatic illness were
associated with the probability of PIP. Improving the quality of prescribing might benefit from an
interprofessional approach and thus better training of physicians and nurses is needed in order to
minimize PIP.
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Medication errors (MEs) happen frequently in hospital settings
and they have been acknowledged as a major problem across
health care systems (1–4). Studies have unanimously shown
that in the wake of MEs, increased mortality, morbidity and
increased costs for society, hospitals and patients follow
(1,5–8). For several years, psychiatry received little attention
in the context of patient safety but in 2006 the Institute of
Medicine report Preventing Medication Errors concluded that
MEs needed further study in mental health settings (9).
Following the report, it has been demonstrated that prescrib-
ing errors in psychiatry are a frequent problem and may
potentially harm patients (10–16). The terminology used in this
study is shown in Table 1 (1,17–21).
Prescribing drugs for adult psychiatric patients is a highly
complex task due to the nature of psychiatric conditions and
somatic co-morbidity (22,23). Consequently, balanced prescrib-
ing (19) might be difficult to achieve and prescribing may
become less appropriate. Balanced prescribing encompasses
considerations on drugs prescribed for both psychiatric and
somatic illnesses. This crossfield has rarely been touched upon
in the literature but a French study on inappropriate
prescribing for elderly patients with cognitive or psychiatric
co-morbidity concluded that risk factors for inappropriate
prescriptions amongst others were number of concomitant
prescriptions and being cognitively impaired. Additionally, it
was concluded that risk factors for omission of prescriptions
(under-use) were psychiatric disorders and increased level of
somatic illness (24). The uncertainty of causality and the
complexity physicians face when prescribing drugs for
psychiatric patients increases the risk of potentially inappropri-
ate prescribing (PIP). ‘‘Potentially inappropriate prescribing’’ is
a term that also reflects the subjectivity related to the issue,
e.g. ‘‘appropriateness’’ depends on the quality and relevance of
the evidence, viewpoints of the clinician and patient, and the
patient’s circumstances and treatment goals (25). Nonetheless,
in order to develop realistic, preventive strategies there is a
need to establish the prevalence, type and severity of PIP in
mental health settings. Given the complexity of evaluating the
CONTACT Ann Lykkegaard Soerensen als@business.aau.dk Danish Centre for Healthcare Improvements, Aalborg University, Fibigerstraede 11, 9220 Aalborg,
Denmark
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possible clinical outcome for psychiatric patients, medication
reviews performed by clinical pharmacologists with in-depth
knowledge of psychiatry and somatic illness would presumably
serve as the best available ‘‘golden standard’’. Studies on
medication safety in psychiatry have so far focused on
medication errors and not the general appropriateness of
prescribing, including the under-use of drugs. Therefore the
aims of this study were to identify prevalence and types of PIP,
to assess the severity of potential clinical consequences and to
identify possible predictive factors of PIP in a sample of adult
psychiatric in-patients.
Materials and methods
Study design and setting
This study was designed as a descriptive, cross-sectional study
using medication reviews by clinical pharmacologists to
identify PIP in a psychiatric population. The study was carried
out in the Department of Psychiatry of Aalborg University
Hospital, Denmark, which provides mental health services for
the entire Northern Denmark region (approximately 580 000
individuals). Mental health care for adult psychiatric inpatients
in the Northern Denmark region is organized in 14 specialized
units aimed at acute psychiatry, bipolar disease and depres-
sion, psychotic illnesses and personality and anxiety disorders.
Each year the psychiatric university hospital receives approxi-
mately 2800 adult patients and when patients are admitted to
the psychiatric emergency ward, approximately 70% of the
patients are discharged within 24–72 h.
Study population
This study included data from 226 consecutive patients. The
inclusion criterion was admission due to any psychiatric
condition during a 3-month period (1 September to 31
November 2013) to one of the 14 different units. Patients
with end-stage terminal illness, dual admissions to somatic
hospitals, non-obtainable medical records or no prescriptions
were excluded. The patients were admitted by their general
practitioner or via the psychiatric emergency ward. Forensic
and child/adolescent patients were not included in the study.
Data collection
There is no universally accepted definition of medication
review but it has been described as a systematic assessment of
the pharmacotherapy of an individual patient that aims to
evaluate and optimize patient medication by a change (or not)
in prescription, either by a recommendation or via a direct
change (26). The medication reviews in this study followed a 3-
step procedure illustrated in Figure 1, which is a procedure
adapted from a Danish PhD thesis implementing medication
reviews by clinical pharmacologists (27).
Patient interview and documented recommendations to the
ward physician are included in the original procedure (26) but
were omitted in this present study (except for findings of
utmost urgency). Patient interviews as an addition to usual care
were left out because it was assessed that patients would be
needlessly burdened in an already vulnerable situation.
Reporting to the hospital physician was left out due to the
study’s descriptive rather than interventional design. All
identified PIPs were categorized according to types of decision
errors in the prescribing stage of the medication process (17).
Categories and descriptions of PIPs are listed in Table 2.
The clinical pharmacologists also assessed the potential
severity of each PIP using a 4-point scale (potentially non-
significant, potentially significant, potentially serious and
potentially fatal) which was applied in a previous study of
errors in the medication process (13). The 4-point scale is
reproduced in Table 3.
Ethics
The study was approved by the Danish Health and Medicines
Authority, The Danish Data Protection Agency and the hospital
management, but did not require permission from the
Regional Scientific Ethics Committee. According to national
legislation, patient consent was not obtained because the
study was an internal audit of the quality of treatment in the
psychiatric hospital. The clinical pharmacologists were ethically
obliged to intervene if the medication review called for
immediate response. A clinical pharmacologist contacted a
ward on two occasions and the patients’ medications were
reviewed and altered in collaboration with a ward physician.
Table 1. Terminology and definitions.
Terminology Definition
Medication error (ME) An error in the stages of the medication process – ordering, dispensing, administering, and monitoring the
effect – causing harm or implying a risk of harming the patient (17)
Adverse drug events (ADEs) Any injury resulting from medication use, including physical harm, mental harm, or loss of function (1)
Adverse reaction (AR) An adverse reaction is a response to a medicinal product which is noxious and unintended; this includes adverse
reactions which arise from
 Use of a medicinal product within the terms of the marketing authorization
 Use outside the marketing authorization including overdose, misuse, abuse and medication errors
 Occupational exposure (18)
Balanced prescribing A process that recommends a medicine appropriate to the patient’s condition and, within the limits created by




Prescribing that introduces a significant risk of an adverse drug-related event where there is evidence for an
equally or more effective but lower-risk alternative therapy available for the same condition. Additionally, PIP
includes the use of drug combinations with known drug–drug interactions, drug–disease interactions, over-
dosing, use of drugs for longer time than clinically indicated, as well as lack of prescribing drugs that are
clinically indicated (20,21)
Pro re nata (PRN) A prescribed medication which is not scheduled but administered as needed.
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Results
Patients
There were 226 patients admitted during the study period
(1 September to 31 November 2013) and 19 patients were
excluded. Of the 19 patients excluded two were terminally ill,
three had a ‘‘dual’’ admission to a somatic hospital where they
were hospitalized, for two patients it was not possible to gain
access to the patients’ medical records, and the remaining
twelve patients were not prescribed any drugs and were thus
not eligible, resulting in 207 patients (Figure 1). The demo-
graphic data for the patients are displayed in Table 4.
It was found that 71/207(33%) of the patients had one or
more somatic diagnoses. The 207 patients included in the
study represented 1291 prescriptions distributed in 900 regular
prescriptions and 391 PRN prescriptions, respectively.
Step 1.
An overview of the patient’s diagnoses, symptoms, relevant paraclinical data, presence of
medical allergies and other information in the electronic patient record (EPR).
Step 2.
An assessment of the drug treatment according to the EPR and the Electronic Medication Record
(EMR), including information on drug name and dose, duration of treatment, indication, effects,
side-effects as well as information on use of over-the-counter medication, herbal medicine,
vitamins and homeopathic medicine.
Step 3.
Hereafter, a critical review of the medication list will be performed, where the following will be
considered for each drug and patient 
a. Are there still indications for the drugs?
b. The medication is examined in conjunction with clinical parameters, e.g.
patient symptoms, diagnoses, and paraclinical parameters, e.g. blood samples,
blood pressure and pulse.
c. Is the dose and method of administration correct?
d. Are there any new treatments or treatment guidelines relevant to the patient?
e. Is the medical treatment correct according to age and status of the patient?
f. Are there any interactions, side effects and double medications?
g. If relevant, it is studied if the treatment goal has been achieved.
h. Are there any untreated symptoms that could be successfully treated with
drugs?
Figure 1. The process of medication review by clinical pharmacologists. Adapted from Bonnerup (27).
Table 2. Categories and descriptions of potentially inappropriate prescribing (PIP).
Categories of potentially inappropriate prescriptions (PIP) Description
Allergy The patient develops an adverse reaction (AR)(18) caused by an abnormal immune response to a
medication
Omission of indication for treatment There is inadequate documentation in the EMR of the indication for treatment
Drug dosage too low The dose is too low to achieve the goal of therapy and/or below the recommended minimum dose in
the EPAR for the drug (http://www.ema.europa.eu/ema/). If the drug is not evaluated by the EMA
then the product resume supplied by the Danish Medicines and Health Authority (https://
sundhedsstyrelsen.dk/da/medicin/find-medicin/produktresumeer) has been applied
Drug dosage too high The dose is above the recommended maximum dose in the EPAR for the drug (http://
www.ema.europa.eu/ema/). If the drug is not evaluated by the EMA then the product resume
supplied by the Danish Medicines and Health Authority (https://sundhedsstyrelsen.dk/da/medicin/
find-medicin/produktresumeer) has been applied
Interaction between drugs The pharmacological result of two or more drugs interacting both pharmacokinetically and
pharmacodynamically
Interaction between drug and disease The drug has the potential to interact with the patient’s underlying illness(es) and cause harm to the
patient
Duplicate drug The duplicate prescribing of the same medication product or the same therapeutic medication class
Inappropriate dosing interval The time intervals between doses are too short or too long to achieve an appropriate clinical outcome
Inappropriate dosing time The drug has been prescribed for an inappropriate time of day
Inappropriate route of administration The drug has been prescribed to be administered via another route than the first choice according to
guidelines and without documentation for the relevance of the route of administration
Inappropriate duration of treatment The duration of therapy is inappropriate according to guidelines
Omission of a potentially useful medication The patient is eligible for drug therapy to treat an existing medical condition or reduce the risk of
developing a medical condition. This assessment should be based on current guidelines
Other E.g. omission of relevant therapeutic drug monitoring or ECGs
EMA: European Medicines Agency; EMR: electronic medication record; EPAR: European Public Assessment Report.
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Potentially inappropriate prescribing
In total, 349 PIP were identified in 207 patients within 1–3 days
after admission. The median number of regular prescriptions in
the study population was four, but 26/207 patients (13%) had
more than 10 regular prescriptions. The proportion of patients
with at least one PIP was 123/207 (59%) and the proportions of
patients with at least one PIP assessed to be potentially serious
or potentially fatal were 69/207 (33%) and 24/207 (12%),
respectively. Categories, frequency and severity of potential
clinical consequences are displayed in Table 5.
The majority of potential problems in the category ‘‘Other’’
were related to identified potential ARs, e.g. sleep distur-
bances, but also problems such as lack of therapeutic drug
monitoring and ECGs, or lack of response to test results that
were out of range. In the category ‘‘Interaction between drug
and disease,’’ cardiac disease occurred most frequently 4/32,
13%) followed by chronic obstructive pulmonary disorder
(3/32, 9%). In total, 45/349 (13%) of all PIP were assessed as
potentially fatal. Of the 32 drug–drug interactions considered
potentially fatal, 15/32 (47%) concerned two or more
antipsychotic drugs and 12/32 (37%) drug–drug interactions
concerned one or more antipsychotic drugs in combination
with antidepressants. The remaining 5/32 (16%) drug–drug
interactions considered potentially fatal involved the drugs
propranolol, erythromycin and simvastatin. Finally, the cate-
gory ‘‘Omission of a potentially useful medication’’ only
constituted 16/349 (5%) of all PIP but all omissions referred
to medications for somatic illness.
Characteristics and high-risk drugs associated with
potential inappropriate prescribing
The logistic regression analyses of factors which may be
predictors of PIP are presented in Table 6. Only polypharmacy
(45 prescriptions) and number of somatic diagnoses had a
significant predictive value for PIP.
Subgroup analysis combining potentially severe and poten-
tially fatal PIPs showed that polypharmacy (45 prescriptions)
produced a higher risk of potentially harming patients
(RR¼ 2.42, 95% CI¼ 1.64–3.56) than compared to patients
receiving 5 or fewer prescriptions. Additionally, when compar-
ing patients with somatic diagnoses to patients without
somatic diagnoses it produced a higher risk of potentially
severe or potentially fatal PIPs (RR¼ 1.96, 95% CI¼ 1.41–2.72).
These PIP with the potential to harm patients also included
somatic drugs, for example: NSAIDs, antibiotics and beta-
blockers. Antipsychotics were the drugs most often associated
with potentially serious and potentially fatal PIP and this trend
remained unchanged when analysing patients with and
without somatic diagnoses separately. The prevalence of
each unique PIP is low and might only appear a few times in
the dataset because the number and combinations of
individual medications are vast. Any analyses in which each
unique PIP was excluded one by one, did not significantly alter
the estimates on potential severity.
Examples of PIPs assessed to be potentially serious or
potentially fatal can be seen in Table 7 and a table with the
complete number of potentially fatal prescriptions has been
added as Supplementary Table S1.
Discussion
Main results
Our study showed that PIP in newly admitted psychiatric
patients is frequent and poses a major potential threat to
Table 3. Definition of potential clinical consequences.
Category Definition Definition of keywords
Potentially fatal Errors judged to imply a potential clinical risk for
causing the death of the patient
‘‘Fatal’’ refers to errors that could lead to the death
of the patient
Potentially serious Errors judged to imply a potential clinical risk of
injuring the patient
‘‘Injury’’ includes errors that would require active
treatment to restore the health of the patient. A
potentially serious error would lead to either
permanent or temporary disability
Potentially significant Errors judged to imply a potential clinical risk of being
inconvenient for the patient – without causing any
harm or injury
‘‘Inconvenient’’ refers to unpleasant consequences of
wrong dose/drug omission of dose/drug that
could lead to pain, dizziness. It also refers to any
monitoring of the patient such as extra blood
tests, measurements of blood pressure
Potentially non-significant Errors judged to be without any potential clinical risk
for the patient
‘‘Without clinical risk’’ refers to errors that would not
lead to any injury or inconvenience for the patient
Bold type represents errors with the potential to harm patients.
Reproduced from Lisby M, Nielsen LP, Mainz J. Errors in the medication process: frequency, type, and potential clinical consequences. Int J Qual Health Care. 2005, by
permission of Oxford University Press.




Age (mean (range)) 42 (18–83)
Primary psychiatric conditions (ICD-10)
Schizophrenia and other psychotic disorders 77 37
Affective disorders 68 33
Othera 62 30
Somatic morbidities
Cardiac diseaseb 21 10
Diabetes mellitus 2 17 8
COPD 14 7
Patients with alcohol and/or substance abuse 71 33
COPD: chronic obstructive pulmonary disorder; ICD-10: International Statistical
Classification of Diseases and Related Health Problems, tenth edition.
aOther examples include patients without diagnosis at the time, organic
disorders and developmental disorders.
bCardiac disease includes patients with coronary artery disease, arrhythmias,
congestive heart failure and subsequent conditions thereof.
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patient safety. More than half of all patients had at least one
PIP and the largest category of potentially fatal PIP was drug–
drug interactions. Antipsychotics were most often associated
with drug–drug interactions and potentially fatal PIP regardless
of the patients’ somatic health status. Too high doses of drugs
along with missing indications for the use of a drug also
appeared to be a substantial problem. Polypharmacy (number
of prescriptions45) and having one or more somatic diagnoses
were predictive factors of PIP in general. Additionally,
patients with somatic diagnoses were more often prescribed
PIP with potential to harm than patients without a somatic
diagnosis. Consequently, psychiatric patients with45 prescrip-
tions and one or more somatic diagnoses could be considered
especially vulnerable from a medication safety perspective.
Analysis of the impact of each unique PIP (for example a
particular drug–drug interaction) showed no significant impact
on the estimates and therefore supports robustness of the
analysis.
Strengths and limitations
To our knowledge, this study is the first to utilize systematic
medication reviews performed by clinical pharmacologists in
newly admitted psychiatric inpatients. The strength of this
study was the combination of the pharmacologists’ clinical
knowledge of psychiatric patients and pharmacological exper-
tise. This provided a detailed evaluation of the appropriateness
of the medications prescribed considering patients psychiatric
as well as somatic conditions. However, each PIP was identified
and assessed for potential clinical consequences by one person
who might introduce a less reliable result. Ideally, each PIP
should have been assessed for potential clinical consequences
by two or more clinical pharmacologists and evaluated using
for example a Kappa test statistic or discussed until consensus
was reached. A source for reducing the precision of the
estimates in this study was the fact that the assessments of
severity were of potential events and not factual events.
Table 6. Characteristics of patients prescribed PIPs versus those not prescribed PIPs (N¼ 207).
Patients with PIPa Patients with no PIP
Adjusted logistic regression analysisb
N (%) N (%) OR 95%CI p value
Age (reference group: 40–59)
18–29 years 29 (46) 34 (54) 0.66 0.30–1.44 0.296
30–39 years 26 (68) 12 (32) 1.45 0.59–3.61 0.418
40–59 years 24 49 1
 60 years 24 (73) 9 (27) 0.77 0.29–2.06 0.602
Gender (reference group: male)
Male 54 (57) 41 (43) 1
Female 74 (66) 38 (34) 1.44 0.75–2.76 0.273
Alcohol or substance abuse (reference group:
no alcohol or substance abuse)
No substance abuse 88 (63) 52 (37) 1
Substance abuse 40 (60) 27 (40) 1.16 0.55–2.42 0.702
No. of prescriptions (reference group: 1–5)
1–5 prescriptions 43 (43) 57 (57) 1
 6 85 (79) 22 (21) 3.66 1.88–7.11 50.0001
No. of somatic diagnoses (reference group: 0)
0 somatic diagnoses 66 (51) 63 (49) 1
 1 somatic diagnoses 62 (79) 16 (21) 2.53 1.17–5.48 50.018
Pseudo R2 0.15
The reference group is the category to which all other categories are compared for each variable.
OR: odds ratio. The odds ratios reflect the association between the odds for at least one PIP and the interaction of each variable.
aPotentially inappropriate prescribing (PIP).
bAdjusted for age, gender, substance abuse, number of prescriptions and number of somatic diagnoses using logistic regression considering
each patient as a cluster (N¼ 207).











Category of PIP N % N % N % N % N %
Interaction between drugs 125 36 2 1 42 34 49 39 32 26
Drug dosage too high 56 16 6 10 24 43 22 39 4 7
Omission of indication for treatment 46 13 26 57 11 24 8 17 1 2
Other 38 11 8 21 12 32 17 45 1 3
Interaction between drug and disease 32 9 1 2 12 38 16 50 3 9
Omission of a potentially useful medication 16 5 1 6 7 44 8 50 0 0
Inappropriate dosing interval 11 3 6 55 4 36 1 1 0 0
Drug dosage too small 8 2 0 0 6 75 1 13 1 13
Allergy 6 2 3 50 1 17 0 0 2 33
Duplicate drug 4 1 0 0 2 50 1 25 1 25
Inappropriate dosage time 3 1 1 33 2 67 0 0 0 0
Inappropriate dosage form 3 1 2 67 1 33 0 0 0 0
Inappropriate duration of treatment 1 1 0 0 1 100 0 0 0 0
Inappropriate route of administration 0 0 0 0 0 0 0 0 0 0
Total 349 56 125 123 45
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However, assessing potential events based on available
evidence is proactive in terms of medication safety.
The prescriber of identified PIP might have had rational,
clinical considerations which were not documented or
accessible for the clinical pharmacologists and thus compli-
cated the assessment of severity. Our intention with this study
was to initiate a debate about appropriateness of prescribing
and shed light on the complexity in psychiatry as well as the
attentiveness and skill needed in order to perform medication
reviews. Undoubtedly, if psychiatrists, clinical pharmacologists
or nurses were to discuss each PIP, disagreement would
emerge. Implicit medication reviews and assessments of
potential clinical consequences are complex and not necessa-
rily reliable in every case, but have come across as the best
source of estimating the magnitude of PIP.
The study only included patients whose conditions resulted
in an admission to a bed unit and consequently only represents
a more severely ill psychiatric population. The prescribing
investigated in this study reflected the prescribing culture in
Northern Denmark and cannot necessarily be generalized
outside Northern Denmark. However, the results may generate
hypotheses about the quality and appropriateness of prescrib-
ing in mental health care and requires new and preferably
multicentre studies.
Comparisons with previous literature
It has been suggested that the presence of PIP might be a
measure of the quality of prescribing in the elderly (28) and we
suggest that PIP might also serve as an indicator for the quality
of prescribing in psychiatric patients. Studies on the subject of
inappropriate prescribing use the terms PIP and potential
inappropriate medications (PIMs) interchangeably but we have
chosen to consistently use the term PIP when discussing the
results of this present study.
A review from 2013 reported that the prevalence of PIP in 12
observational studies using the STOPP (Screening Tool of Older
Persońs Prescriptions) criteria ranged from 21.4–79% (29). The
STOPP criteria identify potentially inappropriate medication
use in the elderly. Though this was a wide range for the
prevalence of PIP, it still supported our finding of at least one
PIP in 59% of the admitted patients. It was not possible, per se,
to demonstrate an association between PIP and ADEs in
psychiatric patients but an association between PIP and ADEs
has been shown in studies with the elderly (26,30,31).
An important finding in our study was combination therapy
with antipsychotics as the most frequent PIP and the most
frequent potentially serious or potentially fatal drug–drug
interaction when reviewing psychiatric patients’ general
medication profile. Combination therapy with antipsychotics
has been extensively studied and is mostly recognized as a
practice to be avoided (32). However, for certain categories of
treatment-resistant patients, combination therapy with anti-
psychotics is recommendable and should always be an
intentional pharmacological practice (rational psychopharma-
cotherapy) accompanied by close observation (32). The
practice of combining antipsychotics and antidepressants has
also received attention. For instance, two meta-analyses have
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disorder (MDD) using combination therapy with antipsychotics
and antidepressants. There was some evidence to support
augmentation treatment with second-generation antipsycho-
tics to antidepressants in MDD but the practice was also
associated with a higher risk of adverse events leading to
discontinuation of medication (33,34). This was, at least partly,
in line with our study which indicated that drug–drug
interactions involving antipsychotics and antidepressants are
common and potentially a threat to patients’ lives; for example
due to an increased risk of cardiac arrhythmia.
This study revealed that polypharmacy and having one or
more somatic diagnoses were predictive factors for PIP. This was
partially in line with other studies which have also found an
association between polypharmacy and PIP in the elderly
(35,36). The concomitant use of several drugs is, on the other
hand, a necessary and beneficial part of numerous guidelines on
treating a variety of conditions. However, the higher frequency
of potentially harmful PIP in patients with somatic diagnoses
underlines the vulnerability and complexity of psychiatric
patients in general. A recent study from the USA investigated
the influence of psychiatric co-morbidities on 30-day all-cause
readmissions following hospitalizations for heart failure, acute
myocardial infarction and pneumonia. It was demonstrated that
the rate of readmission for patients with psychiatric co-
morbidity was significantly higher compared with those without
a psychiatric comorbidity and that future interventions to
reduce readmission should consider psychiatric aspects (37).
A literature review from 2014 on high-risk drugs suggested
defining a list of high-risk drugs to improve clinically relevant
patient outcomes through medication reviews (38). The
suggested top twenty list encompassed all of the drugs
known to have caused hospitalization, life-threatening condi-
tions, disabilities and death due to MEs. Taking into account
that we studied potentially serious or potentially fatal PIP and
not factual incidences of a drug causing a serious or fatal ME,
there are numerous overlaps: methotrexate, NSAID, opioids,
acetylic salicylic acid, other anticoagulants, beta-blockers,
antibiotics, sulphonylureas, antipsychotics and antidepressants.
This indicates that drugs and drug classes considered to be
high-risk drugs in general also represent a risk in psychiatric
patients and must be considered when prescribing and
reviewing medications.
Implications
The results of this study imply a much greater awareness
towards drug–drug interactions, particularly with antipsycho-
tics and antidepressants, is needed. Similarly, there is a need to
emphasize cautious prescribing when treating patients with
several drugs and somatic diagnoses. Systematic medication
reviews for all patients performed by clinical pharmacologists
or pharmacists may be a relevant intervention. Nevertheless, in
light of the sparse resources available in most health care
systems, mental health included, we need to investigate other
approaches. Many of the potential problems suggested by the
clinical pharmacologists and predictive factors identified in this
study could be identified by nurses and therefore it might be
beneficial to initiate an interprofessional approach. Nurses are
the group of health care professionals that most often interact
with and observe patients taking medication and thus also
observe and monitor effects and side effects of medications
(39). Due to these specific competencies, nurses would be a
natural member of any multidisciplinary team working on
improving medication safety after having received additional
pharmacological and psychopharmacological training. Nurses’
roles in multidisciplinary teams could possibly be to identify
patients in need of systematic medication review by specialists.
Conclusion
PIP appears to be highly frequent and potentially serious in
psychiatric in-patients. Most PIP was associated with psycho-
pharmacological drugs, especially the use of antipsychotics
and antidepressants. Drug–drug interactions proved to be the
largest category of PIP and accounted for the largest
proportion of PIP assessed to be potentially fatal. This study
indicated patients receiving polypharmacy (45 prescriptions)
and patients with one or more somatic diagnoses as being
potentially more vulnerable to PIP. There is an urgent need to
focus on better training of physicians and nurses in order to
prevent PIP. Future studies on improving medication safety
should include interventions aimed at improving physicians’
knowledge of pharmacology as well as nurses’ knowledge and
understanding of pharmacological safety issues. This would
improve a rapid identification of psychiatric patients who
would benefit from systematic medication reviews.
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35. Fialová D, Topinková E, Gambassi G, Finne-Soveri H, Jónsson P,
Carpenter I, et al. Potentially inappropriate medication use
among elderly home care patients in Europe. JAMA
2005;293:1348–58.
36. Rancourt C, Moisan J, Baillargeon L, Verreault R, Laurin D, Grégoire J.
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